

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 403/06, A61K 31/40 C07D 401/06		A1	(11) International Publication Number: WO 92/06973
			(43) International Publication Date: 30 April 1992 (30.04.92)
(21) International Application Number: PCT/US91/07194		(74) Agents: RICHARDSON, Peter, C. et al.; Patent Department, Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).	
(22) International Filing Date: 8 October 1991 (08.10.91)			
(30) Priority data: 597,928 15 October 1990 (15.10.90) US		(81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), CS, DE (Utility model), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL (European patent), NO, PL, RO, SE (European patent), SN (OAPI patent), SU*, TD (OAPI patent), TG (OAPI patent), US.	
(60) Parent Application or Grant (63) Related by Continuation US 597,928 (CIP) Filed on 15 October 1990 (15.10.90)			
(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MACOR, John, Eugene [US/US]; 42 Ann Avenue, Mystic, CT 06355 (US). WYTHES, Martin, James [GB/GB]; The Retreat, Church Hill, Sutton, Dover, Kent (GB).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: INDOLE DERIVATIVES



(I)

(57) Abstract

Compounds of formula (I), wherein n is 0, 1 or 2; R₁ is hydrogen; R₂ is selected from hydrogen, halogen, cyano, OR₄, -(CH₂)_m-(C=O)NR₅R₆, -(CH₂)_m-SO₂NR₅R₆, -(CH₂)_m-NR₇(C=O)R₈, -(CH₂)_m-NR₇SO₂R₈, -(CH₂)_m-S(O)_xR₈, -(CH₂)_m-NR₇(C=O)NR₅R₆, -(CH₂)_m-NR₇(C=O)OR₉, and -CH=CH(CH₂)_yR₁₀; R₃ is selected from hydrogen and C₁ to C₆ linear or branched alkyl; R₄ is selected from hydrogen, C₁ to C₆ alkyl, and aryl; R₅ and R₆ are independently selected from hydrogen, C₁ to C₆ alkyl, aryl, and C₁ to C₃ alkyl-aryl or R₅ and R₆ taken together to form a 4, 5, or 6 membered ring; R₇ and R₈ are independently selected from hydrogen, C₁ to C₆ alkyl, aryl, and C₁ to C₃ alkyl-aryl; R₉ is selected from hydrogen, C₁ to C₆ alkyl, aryl, and C₁ to C₃ alkyl-aryl; R₁₀ is selected from -(C=O)NR₅R₆ and -SO₂NR₅R₆, wherein R₅ and R₆ are defined as above, and -NR₇(C=O)R₈, -NR₇SO₂R₈, -NR₇(C=O)NR₅R₆, -S(O)_xR₈ and -NR₇(C=O)OR₉, wherein R₇, R₈, and R₉ are as defined above; y is 0, 1, or 2; x is 1 or 2; m is 0, 1, 2, or 3; and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₄ alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C₁ to C₄ alkoxy and the pharmaceutically acceptable salts thereof are new. These compounds are useful psychotherapeutics and are potent serotonin (5-HT₁) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU+	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

-1-

5

INDOLE DERIVATIVESBackground of the Invention

The present invention relates to indole derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The active compounds of the present invention are useful in treating migraine and other disorders.

United States Patents 4,839,377 and 4,855,314 and European Patent Application Publication Number 313397 refer to 5-substituted 3-aminoalkyl indoles. The compounds are said to be useful for the treatment of migraine.


British Patent Application 040279 refers to 3-aminoalkyl-1H-indole-5-thioamides and carboxamides. The compounds are said to be useful in treating hypertension, Raymond's disease and migraine.

European Patent Application Publication Number 303506 refers to 3-poly:hydro-pyridyl-5-substituted-1H-indoles. The compounds are said to have 5HT₁-receptor agonist and vasoconstrictor activity and to be useful in treating migraine.

European Patent Application Publication Number 354777 refers to N-piperidinyl:indolyl:ethyl-alkane sulfonamide derivatives. The compounds are said to have 5HT₁-receptor agonist and vasoconstrictor activity and to be useful in treating cephalic pain.

Summary of the Invention

The present invention relates to compounds of the formula



35

40

-2-

wherein n is 0, 1, or 2; R₁ is hydrogen; R₂ is selected from hydrogen, halogen (e.g., fluorine, chlorine, bromine or iodine), cyano, OR₄, $-(CH_2)_m-(C=O)NR_5R_6$, $-(CH_2)_m-SO_2NR_5R_6$, $-(CH_2)_m-NR_7(C=O)R_8$, $-(CH_2)_m-NR_7SO_2R_8$, $-(CH_2)_m-S(O)_xR_8$, $-(CH_2)_m-$
5 $NR_7(C=O)NR_5R_6$, $-(CH_2)_m-NR_7(C=O)OR_9$, and $-CH=CH(CH_2)_yR_{10}$; R₃ is selected from hydrogen and C₁ to C₆ linear or branched alkyl; R₄ is selected from hydrogen, C₁ to C₆ alkyl, and aryl; R₅ and R₆ are independently selected from hydrogen, C₁ to C₆ alkyl, aryl, and C₁ to C₃ alkyl-aryl or R₅ and R₆ taken together to
10 form a 4, 5, or 6 membered ring; R₇ and R₈ are independently selected from hydrogen, C₁ to C₆ alkyl, aryl, and C₁ to C₃ alkyl-aryl; R₉ is selected from hydrogen, C₁ to C₆ alkyl, aryl, and C₁ to C₃ alkyl-aryl; R₁₀ is selected from $-(C=O)NR_5R_6$ and $-SO_2NR_5R_6$, wherein R₅ and R₆ are defined as above, and
15 $-NR_7(C=O)R_8$, $-NR_7SO_2R_8$, $-NR_7(C=O)NR_5R_6$, $-S(O)_xR_8$ and $-NR_7(C=O)OR_9$, wherein R₇, R₈, and R₉ are as defined above; m is 0, 1, 2, or 3; y is 0, 1, or 2; x is 1 or 2; and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl,
20 wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₄ alkyl, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, cyano, carboxamido, nitro and C₁ to C₄ alkoxy and the pharmaceutically acceptable salts thereof. These compounds
25 are useful in treating migraine and other disorders. Compounds of the formula I wherein R₂ is $-CH=CH-R_{10}$ are also useful as intermediates for preparing other compounds of the formula I.

The compounds of the invention include all optical
30 isomers of formula I (e.g., R and S enantiomers) and their racemic mixtures. The R enantiomers at the designated chiral site in formula I are preferred.

Unless otherwise indicated, the alkyl groups referred to herein, as well as the alkyl moieties of other groups
35 referred to herein (e.g. alkoxy), may be linear or branched,

-3-

and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or be linear or branched and contain cyclic moieties.

Preferred compounds of the invention are compounds of
5 the formula I wherein R_1 is hydrogen; R_2 is $-(CH_2)_m-SO_2NHR_3$, $-(CH_2)_m-NHSO_2R_3$, $-(CH_2)_m-SO_2R_3$, $-(CH_2)_m-(C=O)NHR_3$, or $-(CH_2)_m-NH(C=O)R_3$; R_3 is hydrogen or methyl; and m , R_3 and R_3 are as defined above and the pharmaceutically acceptable salts thereof. Of the foregoing preferred compounds, the R
10 enantiomers at the designated chiral site in formula I are more preferred.

The following compounds are particularly preferred:

- (R)-5-methoxy-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
15 (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(2-ethylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(2-methylaminosulfonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
20 (R)-5-(2-methylaminosulfonyl-ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(2-methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
25 (R)-5-carboxamido-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(2-methylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-yl-methyl)-1H-indole;
(R)-5-(2-aminosulphonyl-ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
30 (R)-5-(2-aminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
(R)-5-(2-N,N-dimethylaminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
35 (R)-5-(2-phenylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

-4-

- (R)-5-(2-phenylsulphonyethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;
- (R)-5-(2-ethylsulphonyethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;
- 5 (R)-5-(3-benzenecarbonylamino-1-propenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-(4-methylphenylsulphonyl)ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(3-methylsulphonylamino-1-propenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 10 (R)-5-(2-ethylsulphonyethyl)-3-(N-2-propylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-ethylsulphonyethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole;
- 15 (R)-5-(2-(4-methylphenylsulphonyl)ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-methylsulfonamidoethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole; and
- (R)-5-(2-methylsulfonamidomethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole.
- 20
- The following are other specific compounds of the present invention:
- (R)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-fluoro-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 25
- (R)-5-acetylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-benzyloxycarbonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 30 (R)-5-(2-aminocarbonyl)ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-aminocarbonylmethyl-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-methylsulfonamido-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole; and
- 35

-5-

(R)-5-aminosulfonyl-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole.

The present invention also relates to a pharmaceutical composition for treating a condition selected from
5 hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof
10 effective in treating such condition and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission (e.g., depression, anxiety,
15 eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders) comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition
20 and a pharmaceutically acceptable carrier.


The present invention also relates to a method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania
25 and headache associated with vascular disorders comprising administering to a mammal (e.g., a human) requiring such treatment an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition.

30 The present invention also relates to a method for treating disorders arising from deficient serotonergic neurotransmission (e.g., depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache
35 associated with vascular disorders) comprising administering to a mammal (e.g., a human) requiring such treatment an

-6-

amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating such condition.


The present invention also relates to a compound of the
5 formula



10

wherein W is $-\text{CO}_2\text{R}_{11}$ or R_3 ; Q is CH_2 or $\text{C}=\text{O}$; n, R_1 , R_2 and R_3 are as defined for formula I; and R_{11} is selected from C_1 to
15 C_6 alkyl, benzyl and aryl, wherein aryl is as defined above. The compounds of formula V are useful as intermediates in preparing compounds of the formula I.


Accordingly, one group of the foregoing intermediates comprises compounds of the formula



20

25

wherein n, R_1 , R_2 and R_{11} are as defined above and a second group of the foregoing intermediates comprises compounds of the formula



30


35

-7-

wherein n , R_1 , R_3 and R_{10} are as defined above.


Detailed Description of the Invention

Compounds of formula I are prepared by hydride reduction of a compound of the formula



wherein R_1 , R_2 , n and R_{11} are as defined above with a hydride reducing agent in an inert solvent. Suitable hydride reducing agents include lithium aluminum hydride, diborane, 15 lithium borohydride and sodium borohydride. The preferred reagent is lithium aluminum hydride. Suitable solvents include ethers, such as diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane. The preferred solvent is tetrahydrofuran. The reaction is conducted at a temperature 20 of about 30°C to about 100°C., preferably about 65°C to about 70°C.

Compounds of formula I are also prepared by catalytic reduction of a compound of the formula




wherein R_1 , R_3 , n and R_{10} are as defined above under an atmosphere of hydrogen, preferably at a pressure of about 1 to about 3 atmospheres, or using a hydrogen source such as ammonium formate or formic acid in an inert solvent. 35 Suitable catalysts include palladium on carbon, Raney nickel, platinum oxide, rhodium, and ruthenium. The

-8-

preferred catalyst is palladium on carbon. Suitable solvents include C₁ to C₆ alcohols, N,N-dimethylformamide, ethyl acetate, and acetonitrile. The preferred solvent is ethanol. The reaction is conducted at a temperature of about 0°C to about 60°C, most preferably at about 25°C.

Compounds of formula I are also prepared by alkylation of compounds of formula I where R₃=H and R₂ and R₁, are as defined for formula I with alkyl halides in the presence of a base in an inert solvent. Suitable alkyl halides include alkyl halides R³ - Halide where the halide is chloride, bromide and iodide. The preferred halide is iodide, or bromide in the presence of a suitable iodide source such as sodium iodide. Suitable bases include tertiary amines and inorganic bases. The preferred base is sodium carbonate. Suitable solvents include N,N-dimethylacetamide, N,N-dimethylformamide, dimethoxyethane, tetrahydrofuran, dichloromethane, acetonitrile. The preferred solvent is N,N-dimethylacetamide. The reaction is conducted at a temperature of about 0°C to about 150°C, preferably at about 120°C.

The compounds of formula II can be prepared by reacting a magnesium salt of an indole derivative of the formula




25

wherein R₁ and R₂ are defined above, with the acid chloride of an N-CO₂R₁₁-proline, N-CO₂R₁₁-azetidine-2-carboxylic acid, or N-CO₂R₁₁-pipecolinic acid (R, S, or racemate), wherein R₁₁ is defined as above. The indole magnesium salt is first prepared from the reaction of an indole of formula IV with an alkyl or aryl magnesium halide, preferably ethylmagnesium bromide. The reaction is generally conducted in an inert solvent at a temperature between about -30°C and about 65°C, preferably at about 25°C. Suitable solvents include diethyl

35

-9-

ether, tetrahydrofuran, and other alkyl ethers. The preferred solvent is diethyl ether. The acid chloride of proline, azetidine-2-carboxylic acid, or pipecolinic acid is prepared in a separate reaction vessel by reaction of the N-
5 CO₂R₁₁-proline, N-CO₂R₁₁-azetidine-2-carboxylic acid, or N-CO₂R₁₁-pipecolinic acid (R, S, or racemate), with oxalyl chloride in methylene chloride at about -10°C to about 25°C (Helv. Chim. Acta, 1920 (1976)). Suitable solvents include diethyl ether, tetrahydrofuran, other alkyl ethers, and
10 methylene chloride. The proline, azetidine-2-carboxylic acid, or pipecolinic acid is N-substituted with a protecting group to avoid reaction of the nitrogen with the acid chloride when it is formed. Suitable protecting groups are substituted-aryl or substituted-alkyl carbamates (e.g.
15 benzyloxycarbonyl). Preferably, a solution of the N-CO₂R₁₁-proline acid chloride in an inert solvent (e.g., diethyl ether) is added slowly to the solution of the magnesium salt of an indole of formula IV at a temperature of about -30°C to about 50°C, preferably at about 25°C.
20 The compounds of formula III can be prepared by reacting a compound of formula




25 wherein R₁, R₃ and n are defined as above and X is chlorine, bromine or iodine (preferably bromine), with a compound containing a vinyl group (e.g. ethyl vinyl sulfone or N-methylvinylsulfonamide) in the presence of a palladium catalyst, a triarylphosphine and a base in an inert solvent. Suitable catalysts include palladium (II) salts, preferably
30 palladium (II) acetate. Suitable solvents include acetonitrile, N,N-dimethylformamide, and tetrahydrofuran.

-10-


The preferred solvent is acetonitrile. The preferred triarylphosphine is tri-*o*-tolylphosphine. Suitable bases include trisubstituted amines. The preferred base is triethylamine. The reaction is conducted at a temperature of about 25°C to 150°C, most preferably at about 80°C.

Compounds of formula I and intermediates to compounds of formula I can be prepared by hydride reduction of a compound of the formula



15 wherein R_2 , n , and R_{11} are as defined above with a hydride reducing agent in an inert solvent. Suitable hydride reducing agents include lithium aluminum hydride, diborane, lithium borohydride, and sodium amide. The preferred reagent is lithium aluminum hydride. Suitable solvents include ethers, such as diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane. The preferred solvent is tetrahydrofuran. The reduction is conducted at a temperature of about 30°C to about 100°C, preferably about 25 65°C to about 70°C.

Compounds of formula I and intermediates to compounds of formula I can also be prepared by catalytic reduction of a compound of the formula



35


-11-

wherein R_2 , n , and R_{11} are as defined above under an atmosphere of hydrogen, preferably at a pressure of about 1 to 3 atmospheres, or using a hydrogen source such as ammonium formate of formic acid in an inert solvent.

5 Suitable catalysts include palladium on carbon, Raney nickel, and platinum oxide. The preferred catalyst is palladium on carbon. Suitable solvents include C_1 to C_6 alcohols, N,N-dimethylformamide, ethyl acetate, and acetonitrile. The preferred solvent is ethanol. The

10 reaction is conducted at a temperature of about 0°C to about 60°C , preferably at about 25°C .

Compounds of formula VI can be prepared by the transition metal catalyzed cyclization of a compound of the formula



wherein R_2 , n , and R_{11} are as defined above, and X is chlorine, bromine, or iodine (preferably bromine or iodine), and R_{12} is $-\text{OR}_{11}$ as defined above or alkyl, aryl, or

25 trifluoromethyl (preferably trifluoromethyl) in a suitable inert solvent with a phase transfer catalyst and a base. Suitable catalysts include palladium salts such as palladium (II) acetate or palladium (II) chloride (preferably palladium acetate) and rhodium salts, such as


30 tris(triphenyl)rhodium (I) chloride. Suitable solvents include N,N-dimethylformamide, acetonitrile, and N-methylpyrrolidine. The preferred solvent is N,N-dimethylformamide. Suitable phase transfer catalysts include tetraalkylammonium halides, preferably tetra- n -

35 butylammonium chloride. Suitable bases include tertiary amines, sodium hydrogen carbonate, and sodium carbonate.

-12-

The preferred base is triethylamine. The reaction is conducted at a temperature of about 80°C to about 180°C, preferably about 150°C to 160°C.

Compounds of formula VI can also be prepared by hydride reduction of a compound of the formula




10

wherein R_2 , n , and R_{11} are as defined above with a hydride reducing agent in an inert solvent. Suitable hydride reducing agents include lithium borohydride, sodium borohydride, and sodium cyanoborohydride. The preferred reagent is lithium borohydride. Suitable solvents include ethers, such as diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane. The preferred solvent is tetrahydrofuran. The reduction is conducted at a temperature of about 30°C to about 100°C, preferably about 65°C to about 70°C.


20

Compounds of formula VII can be prepared by the Mitsunobu coupling reaction of compounds of formulas

25



30




wherein R_2 , n , R_{11} , and R_{12} are as defined above using a phosphine and an azodicarboxylate in a suitable solvent. Suitable phosphines include trialkylphosphines and triarylphosphines, preferably triphenylphosphine. Suitable azodicarboxylates include dialkyl azodicarboxylates,

35

-13-

preferably diethyl diazodicarboxylate. Suitable solvents include methylene chloride, ethers, including tetrahydrofuran, diethyl ether, and 1,4-dioxane, N-N-dimethylformamide and acetonitrile. The preferred solvent
5 is tetrahydrofuran. The reaction is conducted at a temperature of about 0°C to about 65°C, most preferably at about 25°C.


Compounds of formula VIII, if not available commercially, can be prepared by reacting a compound of
10 formula X



15

wherein R_2 and X are as defined above with the acid chloride or the symmetrical anhydride of $\text{R}_2\text{CO}_2\text{H}$ in a suitable solvent with an suitable base. The preferred acid chloride or anhydride is trifluoroacetic anhydride. Suitable solvents
20 include ethers, including tetrahydrofuran, diethyl ether and 1,4-dioxane, methylene chloride, and chloroform. The preferred solvent is methylene chloride. Suitable bases include triethylamine, pyridine, and sodium hydrogen carbonate. The preferred base is pyridine. The reaction is
25 conducted at a temperature of about 0°C to about 65°C, preferably at about 25°C.

Compounds of formula X, if not available commercially, can be prepared by reacting a compound of formula XI




30

wherein R_2 is as defined above with either chloride, bromine,
35 or iodine in a suitable solvent with a suitable base. Reaction with bromine is preferred. Suitable solvents

-14-

include C₁-C₆ alcohols, methylene chloride, chloroform, or carbon tetrachloride. The preferred solvent is methanol. Suitable bases include triethylamine, pyridine, sodium carbonate, and sodium hydrogen carbonate. The preferred
5 base is sodium hydrogen carbonate. The reaction is conducted at a temperature of about 0°C to about 65°C, preferably at about 25°C.

Compounds of the formula IX can be prepared from
10 hydride reduction of a compound of formula XII




wherein R₁₁ is defined as above and R₁₃ is C₁-C₆ alkyl, aryl, or alkylaryl with a hydride reducing agent in an inert solvent. Suitable hydride reducing agents include lithium
20 aluminum hydride, lithium borohydride, sodium borohydride, and diisobutylaluminum hydride. The preferred reagent is diisobutylaluminum hydride. Suitable solvents include ethers, such as diethyl ether, tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane. The preferred solvent is
25 tetrahydrofuran. The reduction is conducted at a temperature of about -100°C to about 0°C, preferably at about -80°C to about -70°C.

Compounds of the formula XII can be prepared from the Wittig reaction in a suitable solvent involving compounds of
30 the formulas

35

-15-



10 wherein R_{11} and R_{13} are defined as above. Suitable solvents include ethers such as diethyl ether, tetrahydrofuran, and 1,4-dioxane. Tetrahydrofuran is the preferred solvent. The reaction is conducted at a temperature of about -78°C to about 30°C , preferably at about -78°C .

15 Compounds of the formula XIII can be prepared as outlined in S. Kiyooka, et al., J. Org. Chem., 5409 (1989) and Y. Hamada, et al., Chem. Pharm. Bull., 1921 (1982).

Compounds of the formula XIV are either commercially available or can be prepared as outlined in L. Fieser and M. Fieser, Reagents for Organic Synthesis, John Wiley and Sons, New York, Vol. 1, p. 112 (1967).

20 Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically

-16-

acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

Those compounds of the formula I which are also acidic in nature, e.g., where R_2 contains a carboxylate, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be

-17-

prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction of maximum product of yields of the desired final product.

The compounds of the formula I and the pharmaceutically acceptable salts thereof (hereinafter, also referred to as the active compounds of the invention) are useful psychotherapeutics and are potent serotonin (5-HT₁) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, chronic paroxysmal hemicrania and headache associated with vascular disorders, pain, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

The active compounds of the invention are evaluated as anti-migraine agents by testing the extent to which they mimic sumatriptan in contracting the dog isolated saphenous vein strip (P.P.A. Humphrey et al., Br. J. Pharmacol., 94, 1128 (1988)). This effect can be blocked by methiothepin, a known serotonin antagonist. Sumatriptan is known to be useful in the treatment of migraine and produces a selective increase in carotid vascular resistance in the anaesthetized dog. It has been suggested (W. Fenwick et al., Br. J. Pharmacol., 96, 83 (1989)) that this is the basis of its efficacy.

The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or

-18-

in a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form e.g. in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents.

-19-

Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The active compounds of the invention may also be
5 formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration or administration by inhalation, the active compounds of the invention are
10 conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane,
15 trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension
20 of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

25 A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (e.g., migraine) is 0.1 to 200 mg of the active ingredient per unit dose which could be administered,
30 for example, 1 to 4 times per day.

Aerosol formulations for treatment of the conditions referred to above (e.g., migraine) in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains 20 μ g to 1000 μ g of the compound
35 of the invention. The overall daily dose with an aerosol will be within the range 100 μ g to 10 mg. Administration

-20-

may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent. Specific rotations were measured at room temperature using the sodium D line (589 nm).

Commercial reagents were utilized without further purification. Chromatography refers to column chromatography performed using 32-63 μ m silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room temperature refers to 20 - 25°C.

EXAMPLE 1

General Procedure for the Reduction of Benzyloxy-carbonyl-pyrrolidin-2-ylcarbonyl-1H-indole, N-Benzyloxy-carbonyl-azetidin-2-ylcarbonyl-1H-indoles, or N-Benzyloxy-carbonyl-piperidin-2-ylcarbonyl-1H-indoles Forming 3-(N-Methyl-pyrrolidin-2-ylmethyl)-1H-indoles, 3-(N-Methyl-azetidin-2-ylmethyl)-1H-indoles, or 3-(N-Methylpiperidin-2-ylmethyl)-1H-indoles, respectively.

To a stirred solution of (R)- or (S)-(N-benzyloxycarbonylpyrrolidin-2-ylcarbonyl)-1H-indole, (R)-, (S), or (R,S)-(N-benzyloxycarbonylazetidin-2-ylcarbonyl)-1H-indole, or (R)-, (S)-, or (R,S)-(N-benzyloxycarbonylpiperidin-2-ylcarbonyl)-1H-indole, (5.00 mmol) in anhydrous tetrahydrofuran (20mL) at room temperature under nitrogen was carefully added lithium aluminum hydride (0.57 g, 15.0 mmol, 3.0 eq) as a powder, and the resulting mixture was stirred at room temperature under nitrogen for 1 hour. The mixture was then heated at reflux (66°C) under nitrogen for 12 hours. The reaction was then quenched with successive additions of water (0.5 mL), aqueous sodium hydroxide (20%, 0.5 mL), and then additional water (1.0 mL), and the resulting mixture filtered through diatomaceous earth (Celite (trademark)).

-21-

The solids were then washed with copious amounts of ethyl acetate (50 mL). The combined filtrate was then washed with water (20 mL), dried (MgSO_4), and evaporated under reduced pressure. The residue was then column chromatographed using silica gel (50 g) and elution with the appropriate solvent system to afford the 3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 3-(N-methylazetidin-2-ylmethyl)-1H-indole, or 3-(N-methylpiperidin-2-ylmethyl)-1H-indole. Following this procedure the following compounds were prepared:

10 A. (S)-5-Methoxy-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

(S)-(N-Benzyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-methoxy-1H-indole was used. The chromatographic eluent was 8% triethylamine in ethyl acetate to afford the title
15 compound (yields ranged from 22 to 57%) as an oil: IR (CHCl_3) 3475, 1625, 1585, 1480, 1455 cm^{-1} ; ^1H NMR (CDCl_3) δ 8.13 (br s, 1H), 7.23 (d, $J=8.8$ Hz, 1H), 7.04 (d, $J=2.4$ Hz, 1H), 6.97 (d, $J=2.2$ Hz, 1H), 6.84 (dd, $J=2.4$ and 8.8 Hz, 1H), 3.86 (s, 3H), 3.17-3.10 (m, 2H), 2.58 (dd, $J=9.9$ and
20 13.9 Hz, 1H), 2.50-2.40 (m, 1H), 2.47 (s, 3H), 2.26-2.17 (m, 1H), 1.89-1.72 (m, 2H), 1.70-1.52 (m, 2H); ^{13}C NMR (CDCl_3) δ 153.8, 131.4, 128.2, 122.7, 113.9, 111.8, 111.7, 101.1, 66.6, 57.5, 56.0, 40.8, 31.5, 30.0, 21.9; LRMS, m/z (relative intensity) 244 (M^+ , 7), 160 (20), 145 (16), 117
25 (21), 84 (100); HRMS: calculated for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}$: 244.1573; found: 244.1575; $[\alpha]^{25} = -96^\circ$ (CHCl_3 , $c = 1.0$).

B. (R)-5-Methoxy-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

(R)-(N-Benzyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-methoxy-1H-indole was used. The chromatographic eluent was 8% triethylamine in ethyl acetate to afford the title
30 compound (yields ranged from 13 to 61%) as an oil whose spectral and physical properties were identical with the spectral and physical properties of the title compound of
35 Example 1A with the exception of specific rotation of plane

-22-

polarized light: $[\alpha]^{25} = +100^\circ$ (CHCl_3 , $c = 1.0$). HRMS: calculated for $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}$: 244.1573; found: 244.1547.

C. (R)-5-Dibenzylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

5 (R)-3-(N-Benzylloxycarbonylpyrrolidin-2-ylcarbonyl)-5-dibenzylamino-1H-indole was used. Column chromatography using elution with methylene chloride/methanol/ammonium hydroxide [9:1:0.1] afforded the title compound as a pale green foam: ^1H NMR (CDCl_3) δ 7.82 (br s, NH), 7.35-7.19 (m, 10 H), 7.20 (d, $J=8.6$ Hz, 1H), 6.95 (d, $J=2.1$ Hz, 1H), 6.85 (dd, $J=2.3$ and 8.7 Hz, 1H), 6.80 (d, $J=2.2$ Hz, 1H), 4.65 (s, 4H), 3.25-3.02 (m, 2H), 2.52 (dd, $J=9.5$ and 13.9 Hz, 1H), 2.39-2.15 (m, 2 H), 2.30 (s, 3H), 1.85-1.40 (m, 4H); ^{13}C NMR (CDCl_3) δ 143.2, 139.7, 130.5, 128.5, 128.2, 127.3, 126.8, 122.9, 112.5, 112.2, 111.8, 103.4, 67.0, 57.4, 56.4, 40.6, 31.4, 29.7, 21.9. HRMS: calculated for $\text{C}_{28}\text{H}_{31}\text{N}_3$ 409.2520. Found 409.2475.

D. (R)-5-Methoxy-3-(N-methylpiperid-2-ylmethyl)-1H-indole

20 (R)-3-(N-Benzylloxycarbonylpiperid-2-ylcarbonyl)-5-methoxy-1H-indole was used. Column chromatography using elution with 6% triethylamine in ethyl acetate afforded the title compound as a white foam: ^{13}C NMR (CDCl_3) δ 153.7, 131.4, 128.3, 123.3, 113.2, 111.7, 111.6, 101.2, 64.4, 57.2, 55.9, 43.4, 31.0, 28.8, 25.9, 24.1; $[\alpha]^{25} = +67^\circ$ (CDCl_3 , $c=1.0$); HRMS: calculated for $\text{C}_{16}\text{H}_{22}\text{N}_2\text{O}$: 258.1734. Found: 258.1710.

E. (S)-5-Methoxy-3-(N-methylazetidin-2-ylmethyl)-1H-indole

30 (S)-3-(N-Benzylloxycarbonylazetidiny-2-ylcarbonyl)-5-methoxy-1H-indole was used. The chromatographic eluent was 8% triethylamine in ethyl acetate to afford the title compound as a white solid: mp, 118.0-120.0°C; ^{13}C NMR (CDCl_3) δ 153.8, 131.6, 128.0, 122.9, 112.3, 111.9, 111.8, 101.0, 68.5, 56.0, 53.1, 44.7, 32.4, 25.0; $[\alpha]^{25} = -44^\circ$ (CHCl_3 ,

-23-

c=1.0). Anal. calcd for $C_{14}H_{18}N_2O$: C, 73.01; H, 7.88, N, 12.16. Found: C, 72.65; H, 7.91; N, 12.06.

F. (R,S)-5-Methoxy-3-(N-methylazetidin-2-ylmethyl)-1H-indole

5 (R,S)-3-(N-Benzoyloxycarbonylazetidiny1-2-ylcarbonyl)-5-methoxy-1H-indole was used. The chromatographic eluet was 10% triethylamine in ethyl acetate to afford the title compound as a white solid: mp, 116.0-119.0°C; Anal. calcd for $C_{14}H_{18}N_2O$: C, 73.01; H, 7.88; N, 12.16. Found: C, 72.61;
10 H, 7.99; N, 12.10.

EXAMPLE 2

General Method for the Hydrogenation of 5-(2-Sulfonyl-ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indoles to Form 5-(2-Sulfonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indoles

15 A solution of 5-(2-sulfonylethenyl)-3-(N-methylpyrrolidin-2-yl)-1H-indole (0.47 mmol) and 10% Pd/C (0.150 g) in ethanolic hydrogen chloride [prepared from absolute ethanol (10 mL) and acetyl chloride (43 μ L)] and N,
20 N-dimethylformamide (7.5 mL) was shaken under a hydrogen atmosphere (15 psi) at room temperature for 20 hours. The resultant reaction mixture was filtered through diatomaceous earth (Celite (trademark)), washed with absolute ethanol, and the combined filtrates were evaporated under reduced
25 pressure. The residue was partitioned between ethyl acetate and water. The organic phase was separated, washed with water (3x), brine (1x), dried (Na_2SO_4), and evaporated under reduced pressure to afford a yellow oil. Column chromatography of this oil using silica gel and elution with
30 methylene chloride/absolute ethanol/ammonia (90:10:1) afforded the appropriate 5-(2-Ethylsulfonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole. Following this procedure, the following compounds were prepared:

-24-

A. (R)-5-(2-Ethylsulfonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

(R)-5-trans-(2-Ethylsulfonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (Example 4A) was reduced as described above. Chromatography afforded the title compound (0.33 mmol, 70%) as a gum: TLC (CH_2Cl_2 :EtOH: NH_3 , 90:10:1): R_f = 0.3; $[\alpha]^{25} = +62^\circ$ (methanol, $c = 0.10$). Anal. Calcd for $\text{C}_{18}\text{H}_{26}\text{N}_2\text{O}_2\text{S} \cdot 0.05 \text{ CH}_2\text{Cl}_2$: C, 63.21; H, 7.67; N, 8.17; found: C, 63.55; H, 7.61; N, 8.41.

B. (R)-5-(2-Methylaminosulfonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

(R)-5-trans-(2-Methylaminosulfonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (Example 4B) was reduced as described above. Chromatography afforded the title compound (65%) as a foam. Anal. Calcd for $\text{C}_{17}\text{H}_{25}\text{N}_3\text{O}_2\text{S} \cdot 0.1 \text{ CH}_2\text{Cl}_2$: C, 59.71; H, 7.39; N, 12.12; found: C, 59.66; H, 7.14; N, 11.90.

EXAMPLE 3

General Synthesis of 3-(N-Benzylloxycarbonylpyrrolidin-2-ylcarbonyl)-1H-indoles 3-(N-Benzylloxycarbonylazetidyl-2-ylcarbonyl)-1H-indoles, or 3-(N-Benzylloxycarbonylpiperidin-2-ylcarbonyl)-1H-indoles.

Two solutions containing the reactants were prepared separately as follows. To a stirred solution of N-carbobenzylloxypyrrolidine (D or L, 3.10 g, 12.4 mmol, 1 eq) or N-carbobenzylloxylazetidine-2-carboxylic acid (R or S or racemate, 12.4 mmol) or N-carbobenzylloxypiperidine-2-carboxylic acid (R or S or racemate, 12.4 mmol) in anhydrous methylene chloride (7 mL) with one drop dimethylformamide was added oxalyl chloride (1.60 mL, 18.4 mmol, 1.5 eq), and the resulting effervescing solution was stirred at room temperature under nitrogen for 1.5 hours. The solution was then evaporated under reduced pressure, and any remaining solvent was removed from the residual oil using high vacuum to afford the N-benzylloxycarbonylpyrrolidine acid chloride. At the same time, a solution of ethylmagnesium bromide (3.0 M in ether,

-25-

4.13 mL, 12.4 mmol, 1 eq) was added to a stirred solution of the indole (12.4 mmol) in anhydrous ether (50 mL), and this cloudy solution was heated at reflux under nitrogen for 1.5 hours to form the indolemagnesium bromide salt. The proline acid chloride was then dissolved in methylene chloride or ethyl ether (3 mL), and this solution was added dropwise to the stirred solution of the indolemagnesium bromide salt at room temperature, and the resultant reaction mixture was stirred at room temperature under nitrogen for 1 hour. A saturated solution of sodium hydrogen carbonate (25 mL) and ethyl acetate (50 mL) was then added to the reaction mixture, and this mixture was vigorously stirred for 15 minutes. The resulting mixture was filtered through diatomaceous earth (Celite (trademark)), the solids washed with copious amounts of ethyl acetate, and the ethyl acetate layer was separated from the aqueous layer which was extracted with ethyl acetate (2 x 25 mL). All ethyl acetate extracts were combined, dried, and evaporated under reduced pressure. The residual oil/solid was flash chromatographed using silica gel (250 g) and eluted with an appropriate solvent system to afford the desired 3-(N-benzyloxycarbonylpyrrolidin-2-ylcarbonyl)indole, 3-(N-benzyloxycarbonylazetid-2-ylcarbonyl)-1H-indole, or 3-(N-benzyloxycarbonylpiperidin-2-ylcarbonyl)-1H-indole.

25 A. (S)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-methoxy-1H-indole

N-Carbobenzyloxy-L-proline was used. Chromatography using 40-60% ethyl acetate gradient in hexanes afforded the title compound (yields ranged from 27 to 43%) as a white powder. Recrystallization in ethyl acetate/hexanes afforded an analytical sample as a white crystalline solid: mp, 164.0-165.0°C; IR (KBr) 3250, 1695, 1660, 1585, 1520, 1485, 1450, 1425 cm⁻¹; ¹H NMR (CDCl₃) [Note: the spectrum of the title compound appears as a 1:3 mixture of diastereomers due to slow inversion of the amide nitrogen on an NMR time scale. Therefore, the ¹H NMR will be interpreted for each

-26-

compound separately with the more abundant conformer quoted first] δ [more abundant conformer] 9.83 (br s, 1H), 7.53 (d, $J=3.4$ Hz, 1H), 7.42-7.30 (m, 6H), 7.00 (d, $J=8.9$ Hz, 1H), 6.69 (dd, $J=2.4$ and 9.0 Hz, 1H), 5.25 (d, $J=12.9$ Hz, 1H), 5.14 (d, $J=12.5$ Hz, 1H), 5.07-4.99 (m, 1H), 3.74 (s, 3H), 3.78-3.55 (m, 2H), 2.28-1.84 (m, 4H) and δ [less abundant conformer] 9.28 (br s, 1H), 7.90 (d, $J=2.3$ Hz, 1H), 7.59 (d, $J=3.4$ Hz, 1H), 7.24 (d, $J=9.0$ Hz, 1H), 7.06-6.90 (m, 5H), 6.88 (dd, $J=2.7$ and 9.0 Hz, 1H), 5.07-4.99 (m, 2H), 4.96-4.88 (m, 1H), 3.86 (s, 3H), 3.78-3.55 (m, 2H), 2.28-1.84 (m, 4H); LRMS, m/z (relative intensity) 379 (8), 378 (M^+ , 33), 204 (31), 174 (64), 160 (41), 146 (10), 91 (100). Analysis: calculated for $C_{22}H_{22}N_2O_4$: C, 69.83; H, 5.86; N, 7.40; found: C, 69.81; H, 5.67; N, 7.40.

15 **B. (R)-3-(N-Benzoyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-methoxy-1H-indole**

N-Carbobenzyloxy-D-proline was used. Chromatography using 40-60% ethyl acetate gradient in hexanes afforded the title compound (yields ranged from 25 to 36%) as a white powder. Recrystallization in ethyl acetate/hexanes afforded an analytical sample as a white crystalline solid: mp, 165.0-166.0°C. The spectral and physical data for the title compound was identical in all respects with the spectral and physical data of its enantiomer (the title compound of Example 3A); HRMS: calculated for $C_{22}H_{22}N_2O_4$: 378.1582; found: 378.1573.

25 **C. (R)-3-(N-Benzoyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-dibenzylamino-1H-indole**

N-Carbobenzyloxy-D-proline was used. Trituration of the extraction residue with diethyl ether afforded the title compound as a solid: mp, 176.0-177.0°C; LRMS (m/z , relative intensity) 543 (100, M^+), 453 (10), 407 (7), 339 (40), 307 (10), 247 (10), 154 (38); $[\alpha]^{25}_D=+112^\circ$ (THF, $c=1.0$); Anal. calcd for $C_{35}H_{33}N_3O_3$: C, 77.32; H, 6.12; N, 7.73. Found: C, 77.35; H, 6.30; N, 7.66.

-27-

D. (R)-3-(N-Benzylloxycarbonylpiperid-2-ylcarbonyl)-5-methoxy-1H-indole

N-Carbobenzyloxy-D-pipecolinic acid was used. Column chromatography using elution with 10% ether in methylene chloride afforded the title compound as a tan foam: LRMS (m/z, relative intensity) 392 (90, M⁺), 348 (27), 284 (13), 273 (12), 258 (15), 237 (47), 217 (58), 173 (100), HRMS: calculated for C₂₃H₃₃N₃O₂: C, 69.22; H, 5.53; N, 7.69. Found: C, 69.35; H, 5.33; N, 7.64.

10 E. (S)-3-(N-Benzylloxycarbonylazetidiny1-2-ylcarbonyl)-5-methoxy-1H-indole

(S)-N-Carbobenzyloxyazetidine-2-carboxylic acid was used. Trituration of the extract residue with absolute methanol afforded the title compound as a white solid: mp, 15 199.0-200.0°C. Anal. calcd for C₂₁H₂₀N₂O₄: C, 69.22; H, 5.53; N, 7.69. Found: C, 69.35; H, 5.33; N, 7.64.

F. (R,S)-3-(N-Benzylloxycarbonylazetidiny1-2-ylcarbonyl)-5-methoxy-1H-indole

(R,S)-N-Carbobenzyloxyazetidine-2-carboxylic acid was 20 used. Trituration of the extract residue with absolute methanol afforded the title compound as a white solid: mp, 199.0-200.0°C. Anal. calcd for C₂₁H₂₀N₂O₄: C, 69.22; H, 5.53; N, 7.69. Found: C, 68.85; H, 5.47; N, 7.57.

EXAMPLE 4

25 General Method for the Synthesis of 5-trans-(2-Sulfonyl-ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indoles

A mixture of the appropriate vinyl sulfone (1.17 mmol, 1.4 eq), tri-o-tolylphosphine (0.075 g, 0.25 mmol, 0.33 eq), 30 palladium (II) acetate (0.013 g), triethylamine (0.25 mL, 1.79 mmol, 2 eq), and (R)-5-bromo-3-(N-methylpyrrolidinyl-methyl)-1H-indole (0.25 g, 0.85 mmol) in anhydrous acetonitrile (3 mL) was heated at reflux under nitrogen for 17 hours. The resultant reaction mixture was evaporated 35 under reduced pressure, and the residue was column chromatographed using silica gel and

-28-

elution with methylene chloride/absolute ethanol/ammonia (90:8:1) to afford the title compound.

A. (R)-5-trans-(2-Ethylsulfonylethenyl)-3-(N-methyl-pyrrolidin-2-ylmethyl)-1H-indole

5 Ethyl vinyl sulfone was used, and chromatography afforded the title compound (65%) as a white foam: TLC ($\text{CH}_2\text{Cl}_2/\text{EtOH}/\text{NH}_3$, 90:10:1): $R_f = 0.5$. Analysis: calculated for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_2\text{S} \cdot 0.2 \text{ CH}_2\text{Cl}_2$: C, 62.55; H, 7.04; N, 8.02; found: C, 62.65; H, 6.94; N, 7.92.

10 B. (R)-5-trans-(2-Methylaminosulphonylethenyl)-3-(N-methyl-pyrrolidin-2-ylmethyl)-1H-indole

N-methylvinylsulfonamide was used, and chromatography afforded the title compound (71%) as a white foam. Analysis: calculated for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_2\text{S} \cdot 0.1 \text{ CH}_2\text{Cl}_2$: C, 60.06; H, 6.84; N, 12.29; found: C, 59.74; H, 6.77; N, 11.97.

EXAMPLE 5

20 General Procedure for the Hydride Reduction of 3-(N-Benzylloxycarbonyl-pyrrolidin-2-ylmethyl)-1H-indoles and 3-(N-Benzylloxycarbonylpiperid-2-ylmethyl)-1H-indoles Forming 3-(N-Methylpyrrolidin-2-ylmethyl)-1H-indoles and 3-(N-Methylpiperid-2-ylmethyl)-1H-indoles

To a stirred mixture of lithium aluminum hydride (0.152 g, 4.00 mmol, 2 eq) in anhydrous tetrahydrofuran (10 mL) at 0°C was added rapidly a solution of the 3-(N-benzyloxy-carbonylpyrrolidin-2-ylmethyl)-1H-indole or the 3-(N-benzyloxycarbonylpiperid-2-ylmethyl)-1H-indole (2.00 mmol) in anhydrous tetrahydrofuran (5 mL). The resulting mixture is heated at reflux under a nitrogen atmosphere for 3 hours. The reaction mixture is cooled, and water (0.25 mL), 15% aqueous sodium hydroxide (0.25 mL), and then more water (0.75 mL) were added sequentially. The resulting mixture was stirred at 25°C for 30 minutes, filtered, and the filtrate was evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with a solution methylene chloride: methanol: ammonium hydroxide [9:1:0.1] or other appropriate solvent.

-29-

system to afford the corresponding 3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or 3-(N-methylpiperid-2-ylmethyl)-1H-indole.

Following this procedure the following compounds were prepared:

A. (R)-5-(Methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

(R)-3-(N-Benzoyloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole was used. The reaction residue after aqueous work-up as described above was triturated with absolute methanol to afford the title compound as a white solid: mp, 213.0-214.0°C; ¹H NMR (DMSO-d₆) δ 10.9 (br s, indole NH), 7.51 (br d, 1H), 7.31 (d, J=8.3 Hz, 1H), 7.16 (br d, 1H), 7.08 (br dd, J=8.3 Hz, 1H), 6.82 (br q, sulfonamide NH), 4.35 (s, 2H), 3.07-2.95 (m, 2H), 2.54 (d, J=4.7 Hz, 3H), 2.52-2.38 (m, 2H), 2.35 (s, 3H), 2.10 (br, q, J=8.2 Hz, 1H), 1.75-1.40 (m, 4H); [α]_D²⁵=+89° (DMSO-d₆, c=1.0); Anal. calcd for C₁₆H₂₃N₃SO₂: C, 59.79; H, 7.21; N, 13.07. Found: C, 59.66; H, 7.29; N, 12.81.

B. (R)-5-Aminomethyl-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

(R)-3-(N-Benzoyloxycarbonylpyrrolidin-2-ylmethyl)-5-cyano-1H-indole was used. Column chromatography using elution with 9:1:0.1 [methylene chloride:methanol:ammonium hydroxide] afforded the title compound as a white foam: ¹³C NMR δ 135.6, 132.3, 127.5, 123.0, 122.8, 121.4, 117.1, 112.8, 111.5, 66.8, 57.2, 46.4, 40.5, 31.2, 29.2, 21.5; HRMS: calculated for C₁₅H₂₁N₃, 243.1737, found 243.1732.

C. (R,S)-5-(Methylaminosulfonylmethyl)-3-(N-methylpiperid-2-ylmethyl)-1H-indole

(R,S)-3-(N-Benzoyloxycarbonylpiperidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole was used. Column chromatography using elution with 10% triethylamine in ethyl acetate afforded the title compound as a clear, colorless oil: ¹³C NMR (DMSO-d₆) δ 135.9, 127.7, 124.0, 123.6, 121.0, 119.7, 111.9, 111.1, 63.9, 56.7, 56.3, 43.2, 30.5, 29.0,

-30-

27.9, 25.5, 23.7; LRMS (m/z, relative intensity) 336 (1, M⁺), 241 (5), 143 (31), 142 (13), 99 (34), 98 (100), 70 (16); HRMS calculated for C₁₇H₂₃N₃O₂S: 336.1745; found: 336.1756.

EXAMPLE 6

5 General Procedure for the Catalytic Reduction of 3-(N-Benzylloxycarbonylpyrrolidin-2-ylmethyl)-1H-indoles and 3-(N-Benzylloxycarbonylpiperid-2-ylmethyl)-1H-indoles Forming 3-(Pyrrolidin-2-ylmethyl)-1H-indoles and 3-(Piperid-2-ylmethyl)-1H-indoles

10 A mixture of the 3-(N-benzylloxycarbonylpyrrolidin-2-ylmethyl)-1H-indole or the 3-(N-benzylloxycarbonylpiperid-2-ylmethyl)-1H-indole (2.00 mmol), 10% palladium on carbon (0.20 g), and ammonium formate (1.26 g, 20 mmol, 10 eq) in absolute ethanol (15 mL) was stirred under a nitrogen
15 atmosphere for 4 hours. The resulting reaction mixture was filtered through diatomaceous earth, and the filtrate was evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with a solution of methylene chloride: methanol:
20 ammonium hydroxide [8:2:0.2] or other appropriate solvent system to afford the corresponding 3-(pyrrolidin-2-ylmethyl)-1H-indole or 3-(piperid-2-ylmethyl)-1H-indole.

Following this procedure the following compounds were prepared:

25 A. (R)-5-(Methylaminosulfonylmethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole

(R)-3-(N-Benzylloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole was used. Column chromatography as described above afforded the title
30 compound as an off-white gum: ¹³C NMR (DMSO-d₆) δ 135.9, 127.5, 123.8, 123.7, 120.9, 119.7, 112.4, 111.1, 59.2, 56.6, 45.7, 31.1, 31.0, 29.0, 24.6; [α]_D²⁵ = +4° (DMSO-d₆, c=1.0); [α]_D²⁵ = -14° (EtOH/CHCl₃, [1:1], c=1.0); HRMS: calculated for [C₁₅H₂₁N₃O₂S•H⁺]: 308.1433; found: 308.1467.

-31-

B. (R)-5-Cyano-3-(pyrrolidin-2-ylmethyl)-1H-indole

(R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-cyano-1H-indole was used. Column chromatography as described above afforded the title compound as an off-white gum: ¹³C NMR (CDCl₃/CD₃OD) δ 138.1, 127.2, 125.0, 124.4, 124.2, 121.0, 113.4, 112.2, 101.5, 59.5, 50.1, 45.7, 31.3, 30.3, 24.7; LRMS (M/z, relative intensity) 225 (M+, 3), 179 (3), 155 (10), 70 (100); HRMS: calculated for C₁₄H₁₃N₃, 225.1268, found 225.1245.

10 C. (R)-3-(Pyrrolidin-2-ylmethyl)-1H-indole

(R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-1H-indole was used. Evaporation of the filtrate residue directly afforded the title compound as a white foam: ¹H NMR (CDCl₃) δ 9.05 (br s, indole NH), 7.50 (d, J=8.6 Hz, 1H), 7.23 (d, J=8.6 Hz, 1H), 7.12-6.98 (m, 2H), 6.90 (s, 1H), 4.0 (br s, amine NH), 3.36-3.24 (m, 1H), 2.95-2.75 (m, 3H), 2.70-2.58 (m, 1H), 1.85-1.50 (m, 3H), 1.45-1.29 (m, 1H); [α]_D²⁵ = +18° (CHCl₃, c=1.0).

20 D. (R)-5-Methoxy-3-(Pyrrolidin-2-ylmethyl)-1H-indole

(R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-5-methoxy-1H-indole was used. Evaporation of the filtrate residue directly afforded the title compound as a gum: LRMS (m/z, relative intensity) 231 (100, M+), 161 (10), 155 (17), 135 (11), 119 (32); [α]_D²⁵ = -12° (CHCl₃, c=1.0); Anal, calcd for C₁₄H₁₈N₂O^{0.75} C₂H₄O₂ [acetic acid salt]: C, 67.61; H, 7.69; N, 10.17. Found: C, 67.74; H, 7.53; N, 9.90.

25 E. (R,S)-5-(Methylaminosulfonylmethyl)-3-(piperid-2-ylmethyl)-1H-indole

(R,S)-3-(N-Benzyloxycarbonylpiperid-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole was used. Column chromatography as described above afforded the title compound as a clear, colorless oil: ¹³C NMR (DMSO-d₆) δ 136.0, 127.5, 124.2, 123.8, 121.0, 119.8, 111.2, 110.9, 56.8, 56.7, 45.8, 31.7, 31.4, 29.0, 25.0, 23.9; LRMS (m/z, relative intensity) 321 (19, M+), 238 (43), 227 (21), 144 (99), 143

-32-

(100); HRMS: calculated for $C_{16}H_{23}N_3O_2S$: 321.1513; found: 321.1501.

EXAMPLE 7

General Procedure for the Formulation of 3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-1H-indoles and 3-(N-Benzyloxycarbonylpiperid-2-ylmethyl)-1H-indoles Via the Palladium Catalyzed Cyclization of 1-(N-Benzyloxycarbonylpyrrolidin-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl-amino)propenes and 1-(N-Benzyloxycarbonylpiperid-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl-amino)propenes

A mixture of the 1-(N-benzyloxycarbonylpyrrolidin-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl-amino)propene or the 1-(N-benzyloxycarbonylpiperid-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl-amino)propene (2.00 mmol), tetrabutylammonium chloride (2.00 mmol), and palladium(II) acetate (0.089 g, 0.40 mmol, 0.2 eq) in a solution of triethylamine (8 mL) and anhydrous N,N-dimethylformamide (4 mL) was heated at reflux under nitrogen for 2 hours. The resulting reaction mixture was evaporated under reduced pressure, and the residue was partitioned between ethyl acetate (25 mL) and water (25 mL). The ethyl acetate layer was removed, and the aqueous layer was extracted with additional ethyl acetate (25 mL). The organic extracts were combined, dried ($MgSO_4$), and evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with either a diethyl ether gradient in methylene chloride or an acetone gradient in methylene chloride to afford the corresponding 3-(N-benzyloxycarbonylpyrrolidin-2-ylmethyl)-1H-indole or the 3-(N-benzyloxycarbonylpiperid-2-ylmethyl)-1H-indole.

Following this procedure the following compounds were prepared:

A. (R)-3-(N-Benzyloxycarbonylpyrrolidin-2-ylmethyl)-1H-indole

(R)-1-(N-Benzyloxycarbonylpyrrolidin-2-yl)-3-(N-(2-iodophenyl)-N-trifluoroacetyl-amino)propene was used.

-33-

Column chromatography afforded the title compound as a clear, pale brown oil: ^1H NMR (CDCl_3) δ 8.05 (br s, indole NH), 7.49-7.34 (m, 7H), 7.17 (br t, 1H), 7.02 (br s, 1H), 6.95 (br s, 1H), 5.24 (s, 2H), 4.28-4.14 (br m, 1H), 3.52-3.41 (m, 2H), 3.28 (br d, 1H), 2.79-2.63 (m, 1H), 1.90-1.70 (m, 4H); LRMS (m/z, relative intensity) 334 (10, M+), 204 (16), 160 (39), 130 (39), 91 (100).

B. (R)-3-(N-Benzylloxycarbonylpyrrolidin-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole

(R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-methylaminosulfonylmethylphenyl)-N-trifluoroacetyl-amino)propene was used. Column chromatography afforded the title compound as an off-white foam: IR (CHCl_3) 1673, 1410, 1358, 1324, 1118, 1092 cm^{-1} ; LRMS (m/z, relative intensity) 441 (9, M+), 237 (29), 204 (77), 160 (97), 143 (73), 91 (100); HRMS: calculated for $\text{C}_{13}\text{H}_{27}\text{N}_3\text{O}_4\text{S}$: 441.1724; found: 441.1704.

C. (R)-3-(N-Benzylloxycarbonylpyrrolidin-2-ylmethyl)-5-cyano-1H-indole

(R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-cyanophenyl)-N-trifluoroacetyl-amino)propene was used. Column chromatography afforded the title compound as a white foam: IR (1% solution in CHCl_3) 2215, 1687 cm^{-1} ; ^{13}C NMR [Note: due to slow nitrogen inversion two conformers of the products are seen by NMR spectroscopy] (CDCl_3) δ 155.1, 137.9, 137.0, 128.8, 128.5, 128.4, 128.0, 127.8, 124.9, 124.6, 121.0, 114.0, 113.9, 112.1, 102.3, 67.2, 66.7, 58.5, 57.6, 47.0, 46.7, 30.3, 30.0, 29.6, 28.8, 23.6, 22.7. Anal. calcd for $\text{C}_{22}\text{H}_{21}\text{N}_3\text{O}_2 \cdot 0.25 \text{ C}_2\text{H}_4\text{O}_2$ [acetic acid]: C, 72.17; H, 5.92; N, 11.22. Found: C, 72.28; H, 5.76; N, 10.95.

D. (R,S)-3-(N-Benzylloxycarbonylpiperid-2-ylmethyl)-5-(methylaminosulfonylmethyl)-1H-indole

(R,S)-1-(N-Benzylloxycarbonylpiperid-2-yl)-3-(N-(2-bromo-4-methylaminosulfonyl-methylphenyl)-N-trifluoroacetyl-amino)propene was used. Column chromatography afforded the title compound as an off-white foam: ^{13}C NMR

-34-

[Note: due to slow nitrogen inversion two conformers of the products are seen by NMR spectroscopy] (CHCl_3) δ 162.5, 136.9, 136.2, 128.4, 127.6, 124.5, 123.3, 120.8, 120.3, 111.5, 66.8, 57.4, 39.5, 36.5, 31.4, 29.8, 25.8, 25.5, 18.8; LRMS (m/z , relative intensity) 445 (5, M^+), 361 (4), 238 (40), 218 (80), 174 (100), 143 (53); HRMS calculated for $\text{C}_{24}\text{H}_{29}\text{N}_3\text{O}_4\text{S}$: 455.1880; found: 455.1899.

EXAMPLE 8(R)-3-(N-Benzylloxycarbonylpyrrolidin-2-ylmethyl)-5-methoxy-1H-indole

To a stirred mixture of lithium borohydride (0.092 g, 4.22 mmol, 2 eq) in anhydrous tetrahydrofuran (5 mL) at 0°C was added a solution of the (R)-3-(N-benzylloxycarbonylpyrrolidin-2-ylcarbonyl)-5-methoxy-1H-indole (0.80 g, 2.11 mmol) in anhydrous tetrahydrofuran (8 mL). The resultant mixture was heated at reflux under nitrogen for 1 hour. The reaction mixture was cooled, and water (1 mL) was added carefully, followed by ethyl acetate (20 mL). The resultant mixture was stirred at room temperature for 30 minutes, dried (MgSO_4), filtered through diatomaceous earth, and the filtrate was evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with ethyl acetate/hexanes [1:1] afforded (R)-3-(N-benzylloxycarbonylpyrrolidin-2-ylmethyl)-5-methoxy-1H-indole as a colorless gum: ^{13}C NMR [Note: due to slow nitrogen inversion two conformers of the products are seen by NMR spectroscopy] (CDCl_3) δ 162.5, 136.9, 136.2, 128.4, 127.8, 127.6, 124.5, 123.3, 120.8, 120.3, 111.5, 66.8, 57.4, 39.5, 36.5, 31.4, 29.8, 25.8, 25.5, 18.8; LRMS (m/z , relative intensity) 364 (30, M^+), 204 (17), 160 (92), 145 (17), 117 (13), 91 (100). Anal. calcd for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_3 \cdot 0.5 \text{H}_2\text{O}$: C, 70.76; H, 6.75; N, 7.50. Found: C, 70.70; H, 6.94; N, 7.15.

-35-

EXAMPLE 9

General Procedure for the Formation of 1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl amino)propenes and 1-(N-Benzylloxycarbonylpiperid-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl amino)propenes from the Mitsunobu Coupling of 2-Halo-N-trifluoroacetylanilines with 1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene or 1-(N-Benzylloxycarbonylpiperid-2-yl)-3-hydroxypropene

To a stirred mixture of 1-(N-benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene or 1-(N-benzylloxycarbonylpiperid-2-yl)-3-hydroxypropene (R, or S, or racemate 2.00 mmol), the 2-halo-N-trifluoroacetylaniline (2.5 mmol, 1.25 eq), and triphenylphosphine (0.655 g, 2.50 mmol, 1.25 eq) in anhydrous tetrahydrofuran at 0°C under a nitrogen atmosphere was added diethyl azodicarboxylate (0.39 mL, 2.48 mmol, 1.25 eq) dropwise. The reaction solution was slowly warmed to 25°C over the course of 2 hours, and then stirred at 25°C under a nitrogen atmosphere for an additional 12 hours. The resulting reaction solution was evaporated under reduced pressure, and the residue was column chromatographed using silica gel (approximately 50 g) and elution with either a diethyl ether gradient in hexanes or an ethyl acetate gradient in hexanes to afford the corresponding 1-(N-benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl amino)propene or 1-(N-benzylloxycarbonylpiperid-2-yl)-3-(N-(2-halophenyl)-N-trifluoroacetyl amino)propene.

Following this procedure the following compounds were prepared:

A. (R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-iodophenyl)-N-trifluoroacetyl amino)propene

(R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene and 2-iodo-N-trifluoroacetylaniline were used. Column chromatography afforded the title compound as a clear, colorless oil: ¹H NMR (CDCl₃) δ 7.88 (br d, 1H), 7.43-6.89 (m, 10H), 5.70-5.35 (m, 2H), 5.13 (br s, 2H),

-36-

5.00-4.75 (m, 1H), 4.40-4.29 (m, 1H), 3.60-3.42 (m, 3H), 2.05-1.45 (m, 4H); LRMS (FAB, m/z, relative intensity) 559 (100, [MH⁺]), 515 (52), 451 (15), 244 (7).

5 B. (R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-methylaminosulfonylmethylphenyl)-N-trifluoroacetyl amino)propene

(R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene and 2-bromo-4-methylaminosulfonylmethyl-N-trifluoroacetylaniline were used. Column chromatography using elution with 4% acetone in methylene chloride afforded the title compound as a white foam (44%): FAB LRMS (m/z, relative intensity) 620 ([MH⁺ with ⁸¹Br], 618 ([MH⁺ with ⁷⁹Br], 98), 576 (50), 574 (63), 512 (17), 484 (33).

15 C. (R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-(N-(2-bromo-4-cyanophenyl)-N-trifluoroacetyl amino)propene

(R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene and 2-bromo-4-cyano-N-trifluoroacetylaniline were used. Column chromatography using elution with a gradient of diethyl ether (5% - 100%) in methylene chloride afforded the title compound as a clear, colorless oil: IR (CHCl₃) 2231, 1702, 1157 cm⁻¹; LRMS (m/z, relative intensity) 537 ([MH⁺ with ⁸¹Br], 13), 535 ([MH⁺ with ⁷⁹Br], 13), 402 (29), 400 (30), 294 (55), 292 (57), 244 (80), 213 (89), 91 (100); Anal. calcd for C₂₄BrF₃H₂₁N₃O₃•0.2 H₂O: C, 53.39; H, 3.99; N, 7.78. Found: C, 53.25; H, 3.95; N, 7.98.

25 D. (R,S)-1-(N-Benzylloxycarbonylpiperid-2-yl)-3-(N-(2-bromo-4-methylaminosulfonylmethylphenyl)-N-trifluoroacetyl amino)propene

(R,S)-1-(N-Benzylloxycarbonylpiperid-2-yl)-3-hydroxypropene and 2-bromo-4-methylaminosulfonylmethyl-N-trifluoroacetylaniline were used. Column chromatography using elution with 20% acetonitrile in methylene chloride afforded the title compound as a white foam: FAB LRMS (m/z, relative intensity) 634 ([MH⁺ with ⁸¹Br], 26), 632 ([MH⁺ with ⁷⁹Br], 22), 590 (35), 588 (43), 401 (33), 327 (48), 281 (75),

-37-

207 (90), 147 (100); FAB HRMS: calculated for $C_{26}H_{29}BrF_3N_3O_5S^+[H^+]$ 632.1043, found 632.1047 [for ^{79}Br and ^{32}S].

EXAMPLE 10

5 General Synthesis of 2-Halo-N-trifluoroacetylanilines from Reaction of 2-Haloanilines and Trifluoroacetic Anhydride

To a stirred solution of the 2-haloaniline (2.00 mmol) and pyridine (0.18 mL, 2.22 mmol, 1.1 eq) in anhydrous methylene chloride (10 mL) at 0°C under a nitrogen atmosphere was added dropwise trifluoroacetic anhydride (0.31 mL, 2.19 mmol, 1.1 eq). The resultant reaction mixture was stirred at 0°C under a nitrogen atmosphere for 3 hours. A saturated solution of sodium hydrogen carbonate was added (15 mL), and this aqueous mixture was extracted with ethyl acetate (3 x 15 mL). The extracts were combined, dried ($MgSO_4$), and evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with an ethyl acetate gradient in hexanes to afford the corresponding 2-halo-N-trifluoroacetylaniline.

Following this procedure the following compounds were prepared:

A. 2-Iodo-N-trifluoroacetylaniline

2-Iodoaniline was used. Evaporation of the ethyl acetate extracts afforded the title compound directly as a white solid: mp, 105.0-106.5°C; FAB LRMS (m/z relative intensity) 316 ($[MH^+]$, 8), 155 (80), 135 (26), 119 (100); ^{13}C NMR (acetone- d_6) δ 206.2, 140.4, 130.2, 130.1, 128.2.

B. 2-Bromo-4-methylaminosulfonylmethyl-N-trifluoroacetylaniline

2-Bromo-4-methylaminosulfonylmethylaniline was used. Evaporation of the ethyl acetate extracts afforded the title compound directly as a white solid: mp, 164.0-166.0°C. Anal. calcd for $C_{10}H_{10}BrF_3N_2O_3S$: C, 32.02; H, 2.69; N, 7.47. Found: C, 32.18; H, 2.67; N, 7.30.

-38-

C. 2-Bromo-4-cyano-N-trifluoroacetylaniline

2-Bromo-4-aminocarbonylaniline was used. Dehydration of the carboxamide also occurred in this reaction. Column chromatography using ethyl acetate/hexanes afforded the title compound as a white solid: mp, 125-130°C; ¹H NMR (DMSO-d₆) δ 11.6 (br s, NH), 8.37 (d, J=1.8 Hz, 1H), 7.96 (dd, J=1.8 and 8.2 Hz, 1H), 7.71 (d, J=8.2 Hz, 1H).

EXAMPLE 11

General Procedure for the Bromination of Anilines to Form 2-Bromoanilines

To a stirred solution of the aniline (2.00 mmol) and sodium hydrogen carbonate (0.21 g, 2.50 mmol, 1.25 eq) in methanol (10 mL) at 0°C was added dropwise bromine (0.113 mL, 2.19 mmol, 1.1 eq). The resulting reaction mixture was then stirred at 25°C for 30 minutes. The reaction mixture was then evaporated under reduced pressure, and the residue was placed in a saturated solution of sodium hydrogen carbonate (10 mL). This aqueous mixture was extracted with ethyl acetate (3 x 15 mL). The extracts were combined, dried (MgSO₄), and evaporated under reduced pressure. The residue was column chromatographed using silica gel (approximately 50 g) and elution with an appropriate solvent system to afford the corresponding 2-bromoaniline.

Following this procedure the following compounds were prepared:

A. 2-Bromo-4-methylaminosulfonylmethylaniline

4-Methylaminosulfonylmethylaniline (M.D. Dowle, et al. Eur. Pat. Appl. EP225,726) was used. Column chromatography using elution with 40% ethyl acetate in hexanes afforded the title compound as a white solid: mp, 104.0-107.0°C. Anal. calcd for C₈H₁₁BrN₂O₂S: C, 34.42; H, 3.97; N, 10.04. Found: C, 34.66; H, 3.96; N, 9.96.

B. 4-Aminocarbonyl-2-bromoaniline

4-Aminobenzamide was used. Column Chromatography using elution with a ethyl acetate gradient (25-50%) in methylene chloride afforded the title compound as a white solid: mp,

-39-

144.5-146.0°C; ¹H NMR (DMSO-d₆) δ 7.93 (d, J=2.0 Hz, 1H), 7.70 (br s, amide NH), 7.62 (dd, J=2.0 and 8.5 Hz, 1H), 7.05 (br s, amide NH), 6.77 (d, J=8.5 Hz, 1H), 5.85 (s, aniline NH₂).

5

EXAMPLE 12**1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene
or 1-(N-Benzylloxycarbonylpiperid-2-yl)-3-hydroxypropene**

To a stirred solution of either ethyl 3-(N-benzylloxycarbonylpyrrolidin-2-yl)-2-propenoate or ethyl-3-
10 (N-benzylloxycarbonylpiperid-2-yl)-2-propenoate (R, or S, or racemate, 10.00 mmol) in anhydrous tetrahydrofuran (75 mL) at -78°C under nitrogen was added dropwise a solution of diisobutylaluminium hydride (1.0 M in hexanes, 12.0 mL, 22.0 mmol, 2.2 eq). The resulting solution was stirred at -78°C
15 under nitrogen for 30 minutes. The reaction solution was then allowed to warmed to room temperature over the course of 2 hours. A saturated solution of sodium hydrogen carbonate (50 mL) was added, and the aqueous mixture was extracted with ethyl acetate (3 x 50 mL). The extracts were
20 combined, dried (MgSO₄), and evaporated under reduced pressure. Column chromatography of the residue with diethyl ether/hexanes [1:1] afforded either 1-(N-benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene or 1-(N-benzylloxycarbonyl-piperid-2-yl)-3-hydroxypropene.

25 Following the procedure the following compounds were prepared:

A. (R)-1-(N-Benzylloxycarbonylpyrrolidin-2-yl)-3-hydroxypropene

(R)-Ethyl 3-(N-benzylloxycarbonylpyrrolidin-2-yl)-2-pro-
30 penoate was used. Chromatography of the extraction residue afforded the title compound as a clear, colorless oil: ¹H NMR (CDCl₃) δ 7.40-7.25 (m, 5H), 5.75-5.53 (m, 2H), 5.20-5.00 (m, 2H), 4.38 (br m, 1H), 4.06 (br d, J=13.7 Hz, 2H), 3.45 (br t, J=7.0 Hz, 1H), 2.03-1.68 (m, 4H); [α]_D²⁵ = +34° (MeOH, c=1.0); HRMS: calculated for C₁₅H₁₉NO, 261.1365, found 261.1356.

-40-

B. (R,S)-1-(N-Benzylloxycarbonylpiperid-2-yl)-3-hydroxypropene

(R,S)-Ethyl 3-(N-benzylloxycarbonylpiperid-2-yl)-2-propenoate was used. Chromatography of the extraction residue
5 afforded the title compound as a clear, colorless oil: LRMS (m/z, relative intensity) 257 (3), 212 (12), 193 (8), 175 (65), 173 (100), 145 (27), 109 (24), 91 (87); ¹H NMR (CDCl₃) δ 7.40-7.20 (m, 5H), 5.70-5.61 (m, 2H), 5.14 (d, J=17.6 Hz, 1H), 5.10 (d, J=17.5 Hz, 1H), 4.88 (br m, 1H), 4.14-4.00 (m, 3H), 2.91 (br t, J=12.7 Hz, 1H), 1.78-1.47 (m, 6H). Anal.
10 calcd for C₁₆H₂₁NO₃•0.1 H₂O: C, 69.34; H, 7.71; N, 5.05. Found: 69.38; H, 7.84; N, 5.16.

EXAMPLE 13

15 Synthesis of Ethyl 3-(N-Benzylloxycarbonylpyrrolidin-2-yl)-2-propenoate or Ethyl 3-(N-Benzylloxycarbonylpiperid-2-yl)-2-propenoate

To a stirred solution of N-carbobenzylloxypyrrolidine-2-carboxaldehyde or N-carbobenzylloxypiperidine-2-carboxaldehyde (5.00 mmol) [S. Kiyooka, et al., J. Org. Chem., 5409 (1989) and Y. Hamada, et al., Chem. Pharm. Bull., 1921 (1982)] in anhydrous tetrahydrofuran at -78°C was added (carbethoxymethylene)triphenylphosphorane (2.09 g, 6.00 mmol, 1.2 eq) as a solid portionwise. The resulting
20 reaction mixture was stirred at room temperature under nitrogen for 2 hours, and then heated at reflux under nitrogen for 1 hour. The reaction mixture was evaporated under reduced pressure and the residue was column chromatographed using silica gel (approximately 100 g) and elution with 20% diethyl ether in hexanes to afford either
25 ethyl 3-(N-benzylloxycarbonylpyrrolidin-2-yl)-2-propenoate or ethyl 3-(N-benzylloxycarbonylpiperid-2-yl)-2-propenoate.
30

A. (R)-Ethyl 3-(N-Benzylloxycarbonylpyrrolidin-2-yl)-2-propenoate

(R)-N-Carbobenzylloxypyrrolidine-2-carboxaldehyde was
35 used. Chromatography as described above afforded the title compound as a clear, colorless oil: ¹H NMR (CDCl₃-d₆) δ 7.34-

-41-

7.25 (m, 5H), 6.89-6.76 (m, 1H), 5.88-5.74 (m, 1H), 5.18-5.05 (m, 2H), 4.60-4.43 (m, 1H), 4.17 (q, $J=7.1$ Hz, 2H), 3.55-3.40 (m, 2H), 2.11-2.00 (m, 1H), 1.90-1.75 (m, 3H), 1.28 (t, $J=7.1$ Hz, 3H); ^{13}C NMR (CDCl_3) [Note: due to slow nitrogen inversion two conformers of the products are seen by NMR spectroscopy] δ 166.3, 154.7, 147.9, 147.4, 136.6, 128.4, 127.9, 120.9, 66.9, 65.8, 60.4, 58.1, 57.7, 46.8, 46.4, 31.6, 30.8, 23.6, 22.8, 22.6, 15.3, 14.2.

10 B. (R,S)-Ethyl 3-(N-Benzyloxycarbonylpiperid-2-yl)-2-propenoate

(R,S)-N-Carbobenzyloxypiperidine-2-carboxaldehyde was used. Chromatography as described above afforded the title compound as a clear, colorless oil: ^1H NMR ($\text{CDCl}_3\text{-}d_6$) δ 7.36-7.27 (m, 5H), 6.85 (dd, $J=4.4$ and 16.3 Hz, 1H), 5.80 (dd, $J=2.4$ and 16.3 Hz, 1H), 5.11 (s, 2H), 5.01 (br m, 1H), 4.17 (q, $J=6.7$ Hz, 2H), 4.05 (br d, $J=12.6$ Hz, 1H), 2.87 (br t, 1H), 1.80-1.35 (m, 6H), 1.27 (t, $J=6.6$ Hz, 3H); FAB LRMS (m/z , relative intensity) 318 ($[\text{MH}^+]$, 100), 274 (86), 228 (14), 210 (21), 182 (43), 138 (32).

20

EXAMPLE 14

(R)-5-Amino-3-(N-methylpyrrolidin-2-ylmethyl)indole

A mixture of (R)-5-dibenzylamino-3-(N-methylpyrrolidin-2-ylmethyl)indole (1.08 g, 2.64 mmol) and palladium [II] hydroxide on carbon (0.6 g) in absolute ethanol (25 mL) was shaken under a hydrogen atmosphere (3 atm) at 40°C for 4 hours. The resulting mixture was filtered through diatomaceous earth, and the filtrate was evaporated under pressure to afford the title compound (0.60 g, 2.62 mmol, 99%) as a white foam: ^1H NMR ($\text{DMSO-}d_6$) δ 10.65 (br s, NH), 7.14 (d, $J=2.2$ Hz, 1H), 7.12 (d, $J=8.6$ Hz, 1H), 6.85 (d, $J=1.6$ Hz, 1H), 6.60 (dd, $J=2.0$ and 8.6 Hz, 1H), 3.63-2.83 (m, 7H), 2.78 (s, 3H), 2.05-1.67 (m, 4H); $[\alpha]_D^{25}=+9^\circ$ (MeOH, $c=1.0$); HRMS: calculated for $\text{C}_{14}\text{H}_{19}\text{N}_3$: 229.1575; found 229.1593.

-42-

EXAMPLE 15General Synthesis of 5-Carbonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indoles and 5-Sulfonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indoles

5 To a stirred solution of (R)-5-amino-3-(N-methylpyrrolidin-2-ylmethyl)indole (0.229 g, 1.00 mmol) and triethylamine (0.21 mL, 1.5 mmol, 1.5 eq) in anhydrous acetonitrile (3 mL) at 0°C under nitrogen was added the appropriate carbonyl chloride or sulfonyl chloride (1.5
10 mmol, 1.5 eq). The resulting reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then evaporated under reduced pressure, and the residue was column chromatographed using silica gel (approximately 25 g) and elution with an appropriate solvent system afforded the
15 appropriate 5-carbonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole or 5-sulfonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole.

Following this procedure the following compounds were prepared:

20 A. (R)-5-Benzoyloxycarbonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

Benzyl chloroformate was used. Column chromatography using elution with triethylamine/acetone/ethyl acetate [2:10:88] afforded the title compound as an off-white foam:
25 ¹³C NMR (CDCl₃) δ 163.3, 136.4, 133.6, 129.8, 128.6, 128.2, 127.9, 126.0, 123.2, 113.8, 111.4, 110.1, 66.8, 66.5, 57.5, 40.8, 31.5, 29.8, 21.8; LRMS (m/z, relative intensity) 363 (M⁺, 12), 279 (7), 184 (7), 171 (33), 108 (100); HRMS: calculated for C₂₂H₂₅N₃O₂ 363.1949, found 363.1926. Anal.
30 calcd for C₂₂H₂₅N₃O₂•0.4 C₄H₈O₄ [ethyl acetate]: C, 71.09; H, 7.13; N, 10.54. Found: C, 70.82; H, 7.03; N, 10.58.

B. (R)-3-(N-Methylpyrrolidin-2-ylmethyl)-5-methylsulfonamido-1H-indole

Methanesulfonyl chloride was used. Column
35 chromatography using elution with triethylamine/acetone/ethyl acetate [1:3:6] afforded the title compound as a white

-43-

foam: ^{13}C NMR (CDCl_3) δ 134.9, 128.3, 128.2, 123.6, 119.3, 115.0, 113.9, 112.0, 66.7, 57.3, 40.7, 38.7, 31.3, 29.4, 21.7; HRMS: calculated for $\text{C}_{15}\text{H}_{21}\text{N}_3\text{O}_2\text{S}$ [with ^{32}S] 307.1356, found 307.1323.

5 C. (R)-5-Acetylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

Acetyl chloride was used. Column chromatography using elution with triethylamine/acetone/ethyl acetate [1:3:6] afforded the title compound as a white foam: ^{13}C NMR (acetone- d_6) δ 168.3, 134.4, 132.2, 128.7, 124.1, 115.7, 113.8, 111.6, 110.2, 67.3, 58.0, 40.9, 31.9, 30.5, 24.1, 22.5; LRMS (m/z, relative intensity) 271 (M^+ , 39), 241 (4), 207 (5), 187 (20), 144 (20), 84 (100); HRMS: calculated for $\text{C}_{16}\text{H}_{21}\text{N}_3\text{O}$ 271.1686, found 271.1693. Anal. calcd for $\text{C}_{16}\text{H}_{21}\text{N}_3\text{O} \cdot 1.15 \text{ H}_2\text{O}$: C, 65.80; H, 8.04; N, 14.39. Found: C, 65.99; H, 7.90; N, 13.99.

15 D. (R)-5-N,N-Dimethylaminocarbonylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

Dimethylcarbonyl chloride was used. Column chromatography using elution with methylene chloride/methanol/ammonium hydroxide [9:1:0.1] afforded the title compound as an off white foam: ^1H NMR (CDCl_3) δ 8.95 (br s, 1H), 7.49 (br s, 1H), 7.15-7.06 (m, 2H), 6.82 (d, $J=1.9$ Hz, 1H), 6.44 (br s, 1H), 3.12-3.05 (m, 2H), 3.00 (s, 6H), 2.58-2.40 (m, 2H), 2.40 (s, 3H), 2.18 (br q, $J=8.1$ Hz, 1H), 1.83-1.47 (m, 4H); ^{13}C NMR (CDCl_3) δ 157.2, 133.8, 130.5, 127.7, 123.2, 117.8, 113.0, 112.0, 111.3, 66.5, 57.4, 40.6, 36.4, 31.4, 29.8, 21.7; LRMS (m/z, relative intensity) 300 (M^+ , 50), 217 (10), 171 (20), 84 (100); HRMS: calculated for $\text{C}_{17}\text{H}_{24}\text{N}_4\text{O}$ 300.1952, found 300.1957.

25 E. (R)-5-Trifluoroacetylamino-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

Trifluoroacetic anhydride was used. Column chromatography using elution with methylene chloride/methanol/ammonium hydroxide [9:1:0-.1] afforded the title compound as an off white foam: ^1H NMR (CDCl_3) δ 8.99 (br s,

-44-

1H), 7.80 (br s, 1H), 7.27-7.19 (m, 2H), 6.95 (d, $J=1.4$ Hz, 1H), 3.16-3.08 (m, 2H), 2.58 (dd, $J=9.4$ and 13.5 Hz, 1H), 2.57-2.43 (m, 1H), 2.43 (m, 1H), 2.43 (s, 3H), 2.22 (dd, $J=9.2$ and 17.5 Hz, 1H), 1.85-1.46 (m, 4H); ^{13}C NMR (CDCl_3) δ 134.5, 127.7, 126.9, 123.8, 116.1, 113.9, 111.9, 111.6, 104.1, 66.6, 57.3, 40.6, 31.3, 29.5, 21.7; HRMS: calculated for $\text{C}_{16}\text{H}_{18}\text{F}_3\text{N}_3\text{O}$ 325.1403, found 325.1378.

EXAMPLE 16

10 (R)-3-(N-Methylpyrrolidin-2-ylmethyl)-5-(2-methyl-sulfonamidomethyl)-1H-indole

To a stirred mixture of (R)-5-aminomethyl-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (0.113 g, 0.46 mmol) and pyridine (50 μL , 0.93 mmol, 2.0 eq) in a solution of dimethylformamide and acetonitrile (1:3, respectively, 2 mL total) at 0°C under nitrogen was added methanesulfonyl chloride dropwise (44 μL , 0.56 mmol, 1.3 eq). The resulting reaction solution was stirred at room temperature under nitrogen for 1 hour, and then it was evaporated under reduced pressure. The residual oil was column chromatographed using silica gel (6 g) and elution with methylene chloride/methanol/ammonium hydroxide [9:1:0.1] to afford the title compound (0.044 g, 0.14 mmol, 30%) as a white foam: ^1H NMR (CDCl_3) δ 8.25 (br s, NH), 7.54 (br s, 1H), 7.35 (d, $J=8.4$ Hz, 1H), 7.17 (dd, $J=1.6$ and 8.4 Hz, 1H), 7.06 (d, $J=1.8$ Hz, 1H), 4.78 (br s, NH), 4.42 (s, 2H), 3.20-3.12 (m, 2H), 2.87 (s, 3H), 2.64 (dd, $J=9.4$ and 13.9 Hz, 1H), 2.54-2.43 (m, 1H), 2.47 (s, 3H), 2.25 (dd, $J=9.3$ and 17.3, 1H), 1.86-1.52 (m, 4H); ^{13}C NMR (CDCl_3) δ 135.8, 127.8, 127.3, 123.0, 122.0, 118.5, 113.7, 111.6, 66.7, 57.4, 47.9, 40.9, 40.7, 31.3, 29.5, 21.7; LRMS (m/z relative intensity) 321 (28), 320 (M^+ , 26), 237 (51), 157 (100), 143 (64), 129 (78); HRMS: calculated for $\text{C}_{16}\text{H}_{22}\text{N}_3\text{O}_2\text{S}$ 320.1435, found 320.1453.

-45-

EXAMPLE 17General Synthesis of AllylsulphonamidesA. Allylsulphonamide

The title compound was prepared by the method of M. A. Belous and I. Ya. Postouski, Zhur. Obschei. Khim., 1950, 20, 1701.

B. N-Methylallylsulphonamide

The title compound was prepared by an analogous procedure to above by using methylamine instead of ammonia. Anal. Calcd for $C_5H_{11}NO_2S$: C, 40.25; H, 7.43; N, 9.38. Found: C, 40.51; H, 7.37; N, 9.70.

EXAMPLE 18Preparation of Ethylallylsulphone

The title compound was prepared by the method of R. J. Palmer and C. J. M. Stirling., J. Amer. Chem. Soc., 1980, 102, 7888.

EXAMPLE 19General Synthesis of Vinyl Sulphonamides


Where the required vinylsulphonamide was not commercially available, they were prepared by the following procedure based on the procedure described in Zhur. Obschei. Khim., 1959, 29, 1494.




A. N,N-Dimethylvinylsulphonamide

To a stirred solution of chloroethylsulphonyl chloride (25 g, 153 mmol) in dry diethyl ether (150 mL) at $-10^{\circ}C$, was added dropwise a solution of dimethylamine (30.5 mL, 460 mmol) in dry diethyl ether (100 mL) over 5 minutes. After stirring for 90 minutes at $-10^{\circ}C$ the solution was filtered and evaporated in vacuo. The residue was distilled to give the title compound (9.5 g, 46%): b.p. $120-122^{\circ}C$ (20 mm Hg). Anal. Calcd for $C_4H_9NO_2S$: C, 35.54; H, 6.71; N, 10.36%. Found: C, 35.36; H, 6.37; N, 10.19.

B. The following examples were prepared by the general procedure above, using the appropriate amine starting material. Purification was by distillation or column chromatography.

-46-



R_2N	Isolated Form	Analysis % (Theoretical in brackets)		
		C	H	N
MeNH-	Oil b.p. 93-5°C (0.05 mm Hg)	Literature compound U.S. 3,761,473		
	Oil	47.97 (47.97)	7.41 7.48	7.81 7.99)
	Oil	44.73 (44.70)	6.80 6.88	8.62 8.69)
nPr ₂ N-	Oil	50.37 (50.23)	8.79 8.96	7.68 7.32
nPrNH-	Oil	40.22 (40.24)	7.35 7.43	9.1 9.39)
	Oil	40.51 (40.79)	5.85 6.16	9.35 9.52)
iPrNH-	Oil	40.42 (40.25)	7.33 7.43	9.30 9.39)

EXAMPLE 20**15 General Synthesis of Vinyl Sulphones**

Where the required vinyl sulphone was not commercially available, they were prepared from the corresponding thiols using the procedure described by J. M. Gaillot, Y Gelas-Mialhe and R. Vessiere Can. J. Chem., 1979, 57, 1958. The
 20 following examples are representative.

-47-

RS-CH₂CH₂-OH

R	Isolated Form	Analysis % (Theoretical in brackets)	
		C	H
nPr	Oil 1/6 EtOAc 1/5 H ₂ O	48.68 (48.76)	9.79 (10.06)
nBu	Oil	T.l.c - Rf. 0.26 (SiO ₂ , Ether/Hexane 1:1)	

10

RS-CH₂CH₂-Cl

R	Isolated Form	Analysis % (Theoretical in brackets)	
		C	H
nPr	Oil 1/5 H ₂ O 1/30 CH ₂ Cl ₂	41.63 (41.65)	7.60 (7.69)
nBu	Oil 1.0 H ₂ O	42.31 (42.21)	7.84 (8.27)

20

RSO₂-CH₂CH₂Cl

R	Isolated Form	Analysis % (Theoretical in brackets)	
		C	H
nPr	Oil	34.75 (35.19)	6.68 (6.50)
nBu	Oil 1/5 CH ₂ Cl ₂	38.41 (38.27)	7.01 (6.95)

25

RSO₂-CH=CH₂

R	Isolated Form	Analysis % (Theoretical in brackets)	
		C	H
nBu	Oil	48.95 (48.62)	8.07 (8.16)

30


35

-48-

EXAMPLE 21General Synthesis of indoles with 5-alkenyl substituentsA. (R)-5-trans-(2-N,N-Dimethylaminocarbonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

A mixture of N,N-dimethylacrylamide (134 μ L, 1.3 mmol), tri-o-tolylphosphine (91 mg, 0.3 mmol), palladium (II) acetate (15 mg, 0.07 mmol), triethylamine (280 μ L, 2 mmol) and (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole was dissolved in anhydrous acetonitrile (5 mL) and refluxed for 24 hours under nitrogen. The reaction was partitioned between ethylacetate and aqueous sodium carbonate. The dried (Na_2SO_4) organic phase was evaporated and the residue purified by column chromatography on silica gel, eluting with CH_2Cl_2 : MeOH: NH_4OH 96:3.5:0.5 to afford the title compound as a white foam (145 mg, 47%). Anal. Calcd for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O} \cdot 1/9 \text{ CH}_2\text{Cl}_2$: C, 71.56; H, 7.87; N, 13.10%. Found: C, 71.29; H, 8.15; N, 13.05.


B. The following examples were prepared using the above procedure with the appropriate alkene starting material (available commercially, or prepared by routes outlined in this patent).



-49-

5



10

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] ²⁵ D (c=0.1 MeOH)
		C	H	N	
MeSO ₂ CH=CH	Foam 3/10 CH ₂ Cl ₂	60.45 (60.42)	6.43 6.62	8.33 8.15	
PhSOCH=CH	Foam 1/10 CH ₂ Cl ₂	68.04 (68.24)	6.27 6.27	6.99 7.20	
NH ₂ SO ₂ CH=CH	Foam 1/3 MeOH 1/3 H ₂ O	58.56 (58.39)	6.80 6.85	12.19 12.51	
EtSOCH=CH	Foam 1/20 CH ₂ Cl ₂ 1/4 H ₂ O	66.70 (66.66)	7.35 7.62	8.64 8.62	
 NSO ₂ CH=CH	Foam 1/8 CH ₂ Cl ₂ 1/2 H ₂ O	61.74 (61.49)	6.93 7.22	10.53 10.69	
nBuSO ₂ CH=CH	Foam 1/4 CH ₂ Cl ₂ 1/10 EtOH	63.56 (63.59)	7.77 7.57	7.22 7.25	
Me ₂ NSO ₂ CH=CH	Foam 1/3 H ₂ O	61.14 (61.19)	7.06 7.27	11.57 11.89	

-50-

5


10

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ (c=0.1 MeOH)
		C	H	N	
 NSO ₂ CH=CH	Foam 1/2 CH ₂ Cl ₂ 1/4 H ₂ O	59.64 (59.43)	8.82 7.07	9.83 9.87	
nPr ₂ NSO ₂ CH=CH	Foam 1.0 H ₂ O 1/10 CH ₂ Cl ₂	61.48 (61.72)	7.78 8.25	9.69 9.77	
nPrNHNSO ₂ CH=CH	Foam 1/10 CH ₂ Cl ₂ 1/3 H ₂ O	61.07 (61.01)	7.12 7.49	10.91 11.18	
 NSO ₂ CH=CH	Foam 1/3 CH ₂ Cl ₂ 1 H ₂ O	56.83 (56.39)	6.40 6.87	10.36 10.36	+34°
iPrNHNSO ₂ CH=CH	Foam 1/6 CH ₂ Cl ₂	61.03 (61.27)	7.42 7.33	11.17 11.19	+30°
PhSO ₂ CH ₂ CH=CH	Foam 1/6 CH ₂ Cl ₂	68.21 (68.27)	6.81 6.50	7.15 6.87	
Me ₂ NSO ₂ CH ₂ CH=CH	Foam 1/20 CH ₂ Cl ₂	62.54 (62.55)	7.50 7.46	11.21 11.48	


-51-

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ (c=0.1 MeOH)
		C	H	N	
NH ₂ SO ₂ CH ₂ CH=CH	Foam 0.1 CH ₂ Cl ₂ 1.0 MeOH	58.50 (58.13)	6.93 7.30	11.22 (11.24)	
EtSO ₂ CH ₂ CH=CH	Foam	65.56 (65.86)	7.47 7.56	8.00 (8.06)	
PhCONHCH ₂ CH=CH	Foam 0.1 CH ₂ Cl ₂	75.69 (75.78)	6.97 7.16	10.76 (10.0)	+70°
MeSO ₂ NHCH ₂ CH=CH	Foam 0.1 CH ₂ Cl ₂	61.05 (61.07)	7.31 7.14	11.12 (11.60)	

5
10 C) The following compounds could be prepared by the procedure a) above but using the corresponding beta-chloroethylsulphone as starting material instead of an alkene. These reactions were preferably carried out in the presence of 3-6 equivalents of triethylamine.



20

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ (c=0.1 MeOH)
		C	H	N	
nPrSO ₂ CH=CH	Foam 1/8 CH ₂ Cl ₂ 1/3 H ₂ O	62.63 (63.25)	7.15 7.47	7.71 (7.7)	
	Foam 0.15 CH ₂ Cl ₂	62.22 (62.20)	5.37 5.49	6.52 (6.55)	+48°


25

-52-

EXAMPLE 22**General Procedure for Hydrogenation of 5-alkenylindoles**


A typical procedure is as follows:

- A. (R)-5-(2-Aminosulphonylethyl)-3-(N-methyl-pyrrolidin-2-ylmethyl)-1H-indole
- (R)-5-(2-Aminosulphonylethenyl)-3-(N-methyl-pyrrolidin-2-ylmethyl)-1H-indole (157 mg, 0.5 mmol) was dissolved in absolute ethanol (10 mL) and added to a solution of ethanolic hydrogen chloride 25 ml (prepared from acetyl chloride (38 μ L, 0.53 mmol) and absolute ethanol (25 mL)). 10% palladium-on-carbon (125 mg) was added. This solution was hydrogenated under a hydrogen atmosphere (15 p.s.i.) at room temperature for 18 hours. The resultant reaction mixture was filtered through diatomaceous earth (Celite trademark or Arbocell-trademark)) washed with absolute ethanol and the combined filtrates evaporated in vacuo. The residue was purified by column chromatography on silica gel, eluting with a gradient solvent mixture up to CH_2Cl_2 : MeOH: NH_4OH 93:7:1 to give the title compound as a colourless oil (80 mg, 51%). Anal. Calcd for $\text{C}_{16}\text{H}_{23}\text{N}_3\text{O}_2\text{S} \cdot 1/4 \text{ MeOH} \cdot 1/3 \text{ H}_2\text{O}$: C, 58.21; H, 7.36; N, 12.54. Found: C, 58.60; H, 7.40; N, 12.57. $[\alpha]^{25} = +69^\circ$ (c=0.1, MeOH).
- B. The following examples were prepared by an analogous procedure to a) above.




-53-

5

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ (c=0.1 MeOH)
		C	H	N	
Me ₂ NSO ₂ CH ₂ CH ₂	Oil 1/20 CH ₂ Cl ₂	61.52 (61.31)	7.40 7.57	11.49 11.89	+48°
Me ₂ NCOCH ₂ CH ₂	Oil 1/10 CH ₂ Cl ₂	70.96 (71.29)	8.52 8.46	12.84 13.06	+76.2°
MeSO ₂ CH ₂ CH ₂	Gum 1/4 H ₂ O	62.76 (62.83)	7.29 7.60	8.41 8.62	+63°
EtSOCH ₂ CH ₂	Oil	61.39 (61.27)	7.69 8.03	8.16 7.83	
 NSO ₂ CH ₂ CH ₂	Foam 2/3 H ₂ O	62.73 (62.81)	7.60 8.11	10.64 10.47	+57°
PhSO ₂ CH ₂ CH ₂ CH ₂	Oil 2/3 H ₂ O	67.56 (67.60)	7.27 7.23	8.96 8.65	


10

15

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ (c=0.1 MeOH)
		C	H	N	
NH ₂ SO ₂ CH ₂ CH ₂ CH ₂	Foam 0.65 CH ₂ Cl ₂	56.78 (56.26)	7.16 6.80	10.34 10.75	
 NSO ₂ CH ₂ CH ₂	Foam 1/2 H ₂ O	62.45 (62.47)	7.48 7.86	10.74 10.93	
Me ₂ NSO ₂ CH ₂ CH ₂ CH ₂	Oil 0.1 CH ₂ Cl ₂	62.03 (61.66)	7.76 7.91	10.41 11.16	
ⁿ BuSO ₂ CH ₂ CH ₂	Oil 1/3 CH ₂ Cl ₂	62.28 (62.48)	7.50 7.91	7.23 7.17	+48°
ⁿ PrNH ₂ SO ₂ CH ₂ CH ₂	Foam 1/4 H ₂ O	62.07 (62.01)	7.95 8.06	11.17 11.42	+57°
ⁿ PrSO ₂ CH ₂ CH ₂	Foam 1/20 CH ₂ Cl ₂ 3/4 H ₂ O	62.80 (62.47)	7.72 8.15	7.24 7.65	+50°
ⁿ Pr ₂ NSO ₂ CH ₂ CH ₂	Gum 1.0 H ₂ O	62.28 (62.37)	8.38 8.80	10.03 9.92	+40°

20

-54-

R ²	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ (c=0.1 MeOH)
		C	H	N	
EtSO ₂ CH ₂ CH ₂ CH ₂	Glass 0.5 CH ₂ Cl ₂	59.10 (59.90)	7.57 7.47	7.04 7.18	
 NSO ₂ CH ₂ CH ₂	Foam 1/3 CH ₂ Cl ₂	59.07 (59.56)	7.10 7.15	10.60 10.78	+30°
IPrNHSO ₂ CH ₂ CH ₂	Foam 1/8 CH ₂ Cl ₂	61.59 (61.39)	7.68 7.88	11.15 11.23	+58°

EXAMPLE 23

General Synthesis of (R)-5-(2-Ethylsulphonylethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indoleA. (R)-3-(N-Benzyloxycarbonylpyrrolidin-2-yl-methyl)-5-bromo-1H-indole

(R)-3-(N-Benzyloxycarbonylpyrrolidin-2-yl-carbonyl)-5-bromo-1H-indole (0.67 g, 1.57 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL) and at room temperature under nitrogen was added lithium borohydride (2 molar in tetrahydrofuran) (1.2 mL, 2.4 mmol). The reaction mixture was stirred at room temperature for 3 hours and warmed to reflux for 16 hours. After cooling to room temperature, 2NHCl (10 mL) was added dropwise and the reaction mixture partitioned between ethyl acetate and water. The separated organic phase was washed with saturated aqueous sodium hydrogen carbonate (2x), brine (1x), dried (Na₂SO₄), and evaporated in vacuo to give a colourless oil. Purification by column chromatography on silica gel, eluting with dichloromethane gave the title compound as an oil (0.32 g). TLC (SiO₂:CH₂Cl₂): R_f=0.2.

B. (R)-5-(Ethylsulphonylethenyl)-3-(N-Benzyloxy carbonylpyrrolidin-2-ylmethyl)-1H-indole

The compound from procedure a) above was coupled with ethyl vinylsulphone under standard conditions described above, to give the title compound as a foam. Anal. Calcd for C₂₅H₂₈N₂O₄S•1/8 CH₂Cl₂: C, 65.15; H, 6.15; N, 6.05. Found: C, 65.16; H, 6.17; N, 5.97. [α]_D²⁵ = -50° (0.1, MeOH).

-55-

C. (R)-5-(2-Ethylsulphonyl-ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole

The compound prepared in procedure b) above, was hydrogenated under the standard condition described above, to give the title compound as a foam. Anal. Calcd for $C_{17}H_{24}N_2O_2S \cdot 1/2 CH_2Cl_2$: C, 63.07; H, 7.48; N, 8.63. Found: C, 62.90; H, 7.25; N, 8.58. $[\alpha]^{25} = -11^\circ$ (c=0.1, MeOH).

EXAMPLE 24


10 General Synthesis of (R)-3-(N-alkyl-pyrrolidin-2-ylmethyl)indoles

A. (R)-3-(N-Ethylpyrrolidin-2-ylmethyl)-5-(2-ethylsulphonyl-ethyl)-1H-indole

To a solution of (R)-3-(pyrrolidin-2-ylmethyl)-5-(2-ethylsulphonyl-ethyl)-1H-indole (0.27 g, 0.8 mmol) in dimethylformamide (dried over 4A sieves) (5 mls), was added sodium carbonate (90 mgs) and ethyl iodide (0.07 mls, 0.88 mmol) at room temperature. The mixture was heated at 120°C under nitrogen for 16 hours. After cooling to room temperature the reaction mixture was partitioned between ethyl acetate and water. The separated organic phase was washed with water (3x), dried (Na_2SO_4) and evaporated in vacuo to give an oil. Purification by column chromatography on silica gel, eluting with CH_2Cl_2 : EtOH: NH_4OH (90:10:0.5) gave the title compound as a gum (100 mgs). Anal. Calcd for $C_{19}H_{28}N_2O_2S \cdot 1/4 CH_2Cl_2 \cdot 1/2 H_2O$: C, 61.04; H, 7.85; N, 7.40. Found: C, 60.80; H, 7.69; N, 7.48. $[\alpha]^{25} + 60^\circ$ (c=0.1, MeOH).

B. The following examples were prepared using the procedure described in a) above but with the appropriate alkyl halide in place of ethyl iodide. The alkyl halide could be iodide or bromide with the optional presence of sodium iodide. Solvents used were either dimethylformamide or dimethylacetamide.

-56-



35

R ³	Isolated Form	Analysis % (Theoretical in brackets)			[α] _D ²⁵ c=0.1 MeOH
		C	H	N	
iPr	Gum 1/10 CH ₂ Cl ₂ 1/4 H ₂ O	64.16 (64.29)	8.17 8.24	7.55 7.46	+24°
* CH ₃ CH(CH ₂ CH ₃) (Isomer 1) R.f. 0.40 SiO ₂ , CH ₂ Cl ₂ : MeOH: NH ₃ (90:10:1)	Gum 1/2 CH ₂ Cl ₂ 1/4 H ₂ O	60.68 (60.97)	7.91 7.97	7.08 6.62	-3°
* CH ₃ CH(CH ₂ CH ₃) (Isomer 2 - R.f. 0.38 SiO ₂ , CH ₂ Cl ₂ :MeOH:NH ₃ (90:10:1))	Gum 1/8 CH ₂ Cl ₂	65.19 (65.53)	8.13 8.40	7.45 7.24	+28°
nPr	Gum 1/20 CH ₂ Cl ₂ 3/5 H ₂ O	64.04 (63.77)	8.19 8.36	7.52 7.42	+62°
(CH ₃) ₂ CHCH ₂	Gum 1/2 H ₂ O	65.32 (65.40)	8.49 8.63	6.87 7.26	+80°
* CH ₃ (CH ₂ CH ₂)CHCH ₂ (S-isomer)	Gum 2/3 H ₂ O	65.72 (65.63)	8.82 8.85	7.10 6.96	+85°

EXAMPLE 25**(R)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole**

(R)-5-Bromo-3-(N-methylpyrrolidin-2-yl-methyl)-1H-indole (60 mg, 0.2 mmol) was dissolved in ethanol (1 mL) and hydrogenated over 10% palladium on carbon (45 mg) at 60 p.s.i. of hydrogen pressure at room temperature for 16 hours. The reaction mixture was evaporated to dryness, and the residue partitioned between ethyl acetate and 10% aqueous sodium carbonate. The organic phase was dried (Na₂SO₄), and evaporated in vacuo. The resulting residue was purified by column chromatography on silica gel (eluting

-57-

with 89:10:1 CH₂Cl₂:MeOH:NH₄OH) to give the title compound (28 mg). Anal. Calcd for C₁₄H₁₈N₂•1/8 CH₂Cl₂ C, 75.42; H, 8.18; N, 12.46. Found: C, 75.50; H, 8.51; N, 12.09. $[\alpha]^{25}_D = +60.2^\circ$ (c=0.088, CHCl₃).

5

EXAMPLE 26(R)-3-(N-Benzoyloxycarbonylpyrrolidin-2-ylcarbonyl)-5-bromo-1H-indole

Two solutions containing the reactants were prepared separately as follows: To a stirred solution of N-benzyloxycarbonyl-D-proline (1.0 g) in anhydrous dichloromethane (2 ml) and N,N-dimethylformamide (1 drop) was added oxalyl chloride (0.5 mL), and the resulting solution was stirred at room temperature for 1.5 hours. The solution was evaporated under reduced pressure, and remaining solvent was removed under high vacuum to give the N-benzyloxycarbonyl-D-proline acid chloride. At the same time, a solution of ethyl magnesium bromide (1.4 mL of a 3M solution in ether) was added dropwise over 5 minutes to a stirred solution of 5-bromoindole (0.75 g) in dry ether (18 mL). The mixture was stirred at room temperature for 10 minutes, heated under reflux for 2 hours, then cooled to -30°C. A solution of the above N-benzyloxycarbonyl-D-proline acid chloride in dry ether (4 mL) was added dropwise with stirring, and stirring was continued for a further 1 hour. Ether (12.5 mL) and saturated aqueous sodium bicarbonate (6.5 mL) were added, and the temperature was allowed to rise to room temperature. Stirring was continued for a further 10 minutes and the mixture was filtered. The solid was washed well with ethyl acetate, and the combined filtrate and washings were washed with water, brine and dried (MgSO₄). Evaporation of the solvent gave an oil which was chromatographed on silica gel. Elution with ethyl acetate gave the title compound as a foam (0.82 g):

LRMS, m/z (relative intensity) 428 (M⁺ with ⁸¹Br, 5), 426 (M⁺ with ⁷⁹Br, 5), 224 (19), 222 (21), 204 (62), 160

-58-

(68), 91 (100). Anal Calcd for $C_{21}H_{19}BrN_2O_3$: C, 59.02; H, 4.48; N, 6.56. Found: C, 58.85; H, 4.51; N, 6.38%.

EXAMPLE 27

5 (R)-5-Bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

A solution of (R)-3-(N-benzyloxycarbonyl-pyrrolidin-2-ylcarbonyl)-5-bromo-1H-indole (1.04 g) in dry tetrahydrofuran (20 mL) was added dropwise to a stirred suspension of lithium aluminium hydride (0.27 g) in dry
10 tetrahydrofuran (15 mL) at room temperature under an atmosphere of dry nitrogen. The mixture was heated under reflux with stirring for 18 hours and then cooled. Additional lithium aluminium hydride (50 mg) was added and refluxing was continued for an additional 3 hours.
15 The mixture was again cooled, lithium aluminium hydride (40 mg) was added, and refluxing was continued for a further 18 hours. The mixture was cooled and water (0.44 mL) was carefully added with stirring, followed by 20% aqueous sodium hydroxide (0.44 mL), followed by more
20 water (1.33 mL). The mixture was diluted with ethyl acetate and filtered through Celite (trademark) filter aid. The filtrate was washed with water, brine and then dried (Na_2SO_4). Evaporation of the solvent gave an oil which was chromatographed on silica gel. Elution with
25 dichloromethane/ethanol/concentrated aqueous ammonia (90:10:0.5) gave the title compound as a solid (0.51 g), m.p. 137-140°C (from dichloromethane/hexane); IR (KBr) 1620, 1595, 1570, 1480, 1450, 1435 cm^{-1} ; 1H NMR (DMSO- d_6) δ 11.05 (br s, 1H), 7.65 (br d, 1H), 7.31 (d, $J=8.6$ Hz, 1H), 7.21 (br d, 1H), 7.16 (dd, $J=1.8$ and 8.6 Hz, 1H),
30 3.03-2.94 (m, 2H), 2.47 (dd, $J=9.2$ and 14.0 Hz, 1H), 2.36-2.26 (m, 1H), 2.33 (s, 3H), 2.09 (dd, $J=8.7$ and 17.3 Hz, 1H), 1.73-1.38 (m, 4H); ^{13}C NMR (DMSO- d_6) δ 134.8, 129.5, 124.7, 123.2, 120.7, 113.4, 112.1, 110.9, 66.1,
35 57.0, 40.5, 30.9, 29.1, 21.6; LRMS, m/z (relative intensity) 294 (M^+ with ^{81}Br , 1), 293 (2), 292 (M^+ with

-59-

⁷⁹Br, 1), 210 (14), 208 (15), 154 (8), 129 (42), 128 (19), 101 (26), 85 (57), 84 (100), 83 (30); $[\alpha]^{25} = + 62^\circ$ (methanol, c = 0.10). Anal Calcd for $C_{14}H_{17}N_2Br \cdot 0.25 H_2O$: C, 56.48; H, 5.93; N, 9.41. Found: C, 56.65; H, 5.69; N, 9.23.

EXAMPLE 28

(R)-5-(2-Ethylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

A mixture of (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (0.25 g), ethyl vinyl sulphone (0.14 g), tri-o-tolylphosphine (0.075 g), palladium (II) acetate (0.013 g), triethylamine (0.25 mL) and acetonitrile (3 mL) was heated under reflux for 17 hours in an atmosphere of nitrogen. The mixture was evaporated and the residue was chromatographed on silica gel. Elution with dichloromethane/ethanol/ concentrated aqueous ammonia (90:8:1) gave the title compound as a foam (0.185 g): TLC (dichloromethane/-ethanol/ concentrated aqueous ammonia, 90:10:1): $R_f = 0.5$. Anal. Calcd for $C_{18}H_{24}N_2O_2S \cdot 0.2 CH_2Cl_2$: C, 62.55; H, 7.04; N, 8.02. Found: C, 62.65; H, 6.94; N, 7.92.

EXAMPLE 29

(R)-5-(2-Ethylsulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)1H-indole

(R)-5-(2-Ethylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (157 mg) was dissolved in a mixture of ethanolic hydrogen chloride [prepared by addition of acetyl chloride (0.043 mL) to ethanol (10 mL)], N,N-dimethylformamide (7.5 mL) and water (0.1 mL) and the solution was shaken under a hydrogen atmosphere (15 psi) at room temperature for 18 hours in the presence of 10% palladium on carbon (150 mg). The mixture was filtered through Arbacel (trade mark) filter aid and the residue was washed well with ethanol. The combined filtrate and washings were evaporated under reduced pressure and the residual oil was partitioned between

-60-

ethyl acetate and 2M aqueous sodium carbonate solution. The organic layer was separated, washed three times with water followed by brine and then dried (Na_2SO_4). Evaporation of the solvent gave an oil which was chromatographed on silica gel. Elution with dichloromethane/methanol/ concentrated aqueous ammonia (90:10:1) gave the title compound as a gum (110 mg): TLC ($\text{CH}_2\text{Cl}_2/\text{C}_2\text{H}_5\text{OH}/\text{NH}_3$; 90:10:1): $R_f = 0.3$; $[\alpha]^{25} = +62^\circ$ (methanol, $c = 0.10$). Anal. Calcd for $\text{C}_{18}\text{H}_{26}\text{N}_2\text{O}_2\text{S}$. 0.05 CH_2Cl_2 : C, 63.21; H, 7.67; N, 8.17. Found: C, 63.55; H, 7.61; N, 8.41%.

EXAMPLE 30

(R)-5-(2-Ethylsulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate

A solution of succinic acid (69 mg) in hot ethanol (3.5 mL) was added slowly with stirring to a solution of (R)-5-(2-ethylsulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole free base (390 mg) in ethanol (3.5 mL). The solution was evaporated and the residue was triturated first with ether and then with ethyl acetate to give the title compound as a solid (375 mg): mp $59-62^\circ\text{C}$; $[\alpha]^{25} = +36^\circ$ (methanol, $c = 0.10$). Anal. Calcd for $\text{C}_{18}\text{H}_{26}\text{N}_2\text{O}_2\text{S}$. 0.5 $\text{C}_4\text{H}_6\text{O}_4$. 0.25 $\text{CH}_3\text{CO}_2\text{C}_2\text{H}_5$. 0.5 H_2O : C, 59.00; H, 7.42; N, 6.68. Found: C, 59.17; H, 7.37; N, 6.73.

EXAMPLE 31

(R)-5-(2-Benzenesulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hydrobromide

A mixture of (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (0.25 g), phenylvinylsulphone (0.19 g), tri-*o*-tolylphosphine (0.075 g), palladium (II) acetate (0.0125 g), triethylamine (0.25 mL) and acetonitrile (2.5 mL) was heated under reflux for 42 hours in an atmosphere of nitrogen. The solvent was evaporated and the residue was chromatographed on silica gel. Elution with dichloromethane/methanol/

-61-

concentrated aqueous ammonia (90:10:1) gave the title compound as a foam (0.24 g): Anal. Calcd for $C_{22}H_{24}N_2O_2S$. HBr. 1/3 CH_2Cl_2 : C, 54.77; H, 5.29; N, 5.72. Found: C, 55.00; H, 4.85; N, 5.58.

5

EXAMPLE 32**(R)-5-(2-Benzenesulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole**

A solution of (R)-5-(2-benzenesulphonylethenyl)-3-N-methylpyrrolidin-2-ylmethyl)-1H-indole hydrobromide (0.214 g) and 10% palladium on carbon (0.15 g) in a mixture of absolute ethanol (10 mL), N,N-dimethylformamide (1 mL) and water (2 drops) was shaken under a hydrogen atmosphere (15 psi) at room temperature for 18 hours. The mixture was filtered through Celite (trademark) filter aid and the residue was washed well with ethanol. The combined filtrate and washings were evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 2M aqueous sodium carbonate solution. The organic layer was separated, washed three times with water, followed by brine and dried (Na_2SO_4). Evaporation of the solvent gave a gum which was chromatographed on silica gel. Elution with dichloromethane/methanol/concentrated aqueous ammonia (90:10:0.5) gave the title compound as a foam (0.096 g). Anal. Calcd for $C_{22}H_{26}N_2O_2S$. H_2O : C, 65.97; H, 7.05; N, 7.00. Found: C, 65.51; H, 6.77; N, 7.45.

EXAMPLE 33**(R)-5-(2-Benzenesulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate**

A solution of succinic acid (95 mg) in ethanol (5 mL) was added to a solution of (R)-5-(2-benzenesulphonylethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole free base (620 mg) in ethanol (5 mL). The solution was evaporated to give the title compound as a foam (680 mg): $[\alpha]^{25} = +29^\circ$ (methanol, c = 0.10). Anal.

-62-

Calcd for $C_{22}H_{26}N_2O_2S$. 0.5 $C_4H_6O_4$. 0.33 C_2H_5OH . 0.5 H_2O ;
C, 63.59; H, 6.92; N, 6.01. Found:
C, 63.52; H, 6.91; N, 6.12.

EXAMPLE 34

5 **(R)-5-[2-(4-Methylphenylsulphonyl)ethenyl]-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole**

A mixture of (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole (0.40 g), 4-methylphenylvinylsulphone (0.273 g), tri-o-tolylphosphine (0.085 g),
10 palladium (II) acetate (0.031 g), triethylamine (0.42 g), and acetonitrile (20 mL) was heated under reflux for 16 hours in an atmosphere of nitrogen. The mixture was cooled and partitioned between ethyl acetate and 10% aqueous sodium bicarbonate solution. The organic
15 layer was washed with brine, dried (Na_2SO_4) and evaporated. The residual orange oil was chromatographed on silica gel. Elution was commenced with dichloromethane/methanol (90:10), followed by dichloromethane/methanol/concentrated aqueous ammonia
20 (90:10:0.25), gradually increasing the concentration of concentrated aqueous ammonia to 1%. The later product-containing fractions were evaporated to give the title compound as a foam (226 mg): $[\alpha]^{25} = +71^\circ$ (methanol, $c = 0.10$). Anal. Calcd for $C_{23}H_{28}N_2O_2S$. 0.15 CH_2Cl_2 : C, 68.27;
25 H, 6.51; N, 6.88. Found: C, 68.26; H, 6.54; N, 6.99.

EXAMPLE 35

(R)-5-[2-(4-Methylphenylsulphonyl)ethyl]-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole

A solution of (R)-5-[2-(4-methylphenylsulphonyl)ethenyl]-3-(N-methylpyrrolidin-2-ylmethyl)-
30 1H-indole (0.18 g) and 10% palladium on carbon (0.20 g) in ethanolic hydrogen chloride [prepared from absolute ethanol (25 mL) and acetyl chloride (35 μ L)] was shaken under a hydrogen atmosphere (15 psi) at room temperature
35 for 16 hours. The reaction mixture was filtered through Celite (trademark) filter aid and the residue was washed


-63-

well with ethanol. The combined filtrate and washings were evaporated under reduced pressure and the residue was partitioned between ethyl acetate and 2M aqueous sodium carbonate solution. The organic layer was
5 saturated, washed three times with water, followed by brine and dried (Na_2SO_4). Evaporation of the solvent gave a gum which was chromatographed on silica gel. Elution with dichloromethane/methanol/concentrated aqueous ammonia (90:10:0.25) gave the title compound as a foam
10 (108 mg): $[\alpha]^{25} = +30^\circ$ (methanol, $c = 0.10$). Anal. Calcd for $\text{C}_{23}\text{H}_{28}\text{N}_2\text{O}_2\text{S}$. 0.05 CH_2Cl_2 . 0.5 H_2O : C, 67.55; H, 7.15; N, 6.84. Found: C, 67.51; H, 7.04; N, 6.98.

-64-

CLAIMS

1. A compound of the formula



I

wherein n is 0, 1, or 2; R_1 is hydrogen; R_2 is selected from hydrogen, halogen, cyano, OR_4 , $-(CH_2)_m-(C=O)NR_5R_6$, $-(CH_2)_m-SO_2NR_5R_6$, $-(CH_2)_m-NR_7(C=O)R_8$, $-(CH_2)_m-NR_7SO_2R_8$, $-(CH_2)_m-S(O)_xR_8$, $-(CH_2)_m-NR_7(C=O)NR_5R_6$, $-(CH_2)_m-NR_7(C=O)OR_9$, and $-CH=CH(CH_2)_yR_{10}$; R_3 is selected from hydrogen and C_1 to C_6 linear or branched alkyl; R_4 is selected from hydrogen, C_1 to C_6 alkyl, and aryl; R_5 and R_6 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl or R_5 and R_6 taken together to form a 4, 5, or 6 membered ring; R_7 and R_8 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_9 is selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_{10} is selected from $-(C=O)NR_5R_6$ and $-SO_2NR_5R_6$, wherein R_5 and R_6 are defined as above, and $-NR_7(C=O)R_8$, $-NR_7SO_2R_8$, $-NR_7(C=O)NR_5R_6$, $-S(O)_xR_8$ and $-NR_7(C=O)OR_9$, wherein R_7 , R_8 , and R_9 are as defined above; y is 0, 1, or 2; x is 1 or 2; m is 0, 1, 2, or 3; and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy and the pharmaceutically acceptable salts thereof.

2. The R enantiomer of a compound according to claim 1.

-65-

3. A compound according to claim 1 wherein R_1 is hydrogen; R_2 is $-(CH_2)_m-SO_2NHR_3$, $-(CH_2)_m-NHSO_2R_3$, $-(CH_2)_m-SO_2R_3$, $-(CH_2)_m-(C=O)NHR_3$, or $-(CH_2)_m-NH(C=O)R_3$; R_3 is hydrogen or methyl; and m , R_3 and R_3 are as defined in claim 1.

4. A compound according to claim 1, said compound being selected from:

- (R)-5-methoxy-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 10 (R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-ethylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-methylaminosulfonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 15 (R)-5-(2-methylaminosulfonyl-ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 20 (R)-5-carboxamido-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-methylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-yl-methyl)-1H-indole;
- (R)-5-(2-methylsulfonylamidoethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 25 (R)-5-(2-aminosulphonyl-ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-aminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- 30 (R)-5-(2-N,N-dimethylaminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;
- (R)-5-(2-phenylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;
- (R)-5-(2-ethylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;
- 35

-66-

(R)-5-(2-phenylsulphonyl ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(3-benzenecarbonylamino prop-1-enyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

5 (R)-5-(2-(4-methylphenylsulphonyl) ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(3-methylsulphonylamino prop-1-enyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

10 (R)-5-(2-ethylsulphonyl ethyl)-3-(N-2-propylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-ethylsulphonyl ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-(4-methylphenylsulphonyl) ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole; and

15 (R)-5-(2-methylsulfonylamido methyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole.

5. A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster
20 headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.

25 6. A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim 1 effective in treating such a disorder and a pharmaceutically acceptable carrier.


30 7. A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a
35 mammal requiring such treatment an amount of a compound

-67-

according to claim 1 effective in treating such condition.

8. A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such a disorder.

9. A compound of the formula



15 wherein W is $-\text{CO}_2\text{R}_{11}$ or R_3 ; Q is CH_2 or $\text{C}=\text{O}$; n is 0, 1 or 2; R_1 is hydrogen; R_2 is selected from hydrogen, halogen, cyano, OR_4 , $-(\text{CH}_2)_m-(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{SO}_2\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{R}_8$, $-(\text{CH}_2)_m-\text{NR}_7\text{SO}_2\text{R}_8$, $-(\text{CH}_2)_m-\text{S}(\text{O})_x\text{R}_8$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{OR}_9$, and $-\text{CH}=\text{CH}(\text{CH}_2)_y\text{R}_{10}$; x is 1 or 2; m is 0, 1, 2, or 3; R_3 is selected from hydrogen and C_1 to C_6 linear or branched alkyl; R_4 is selected from hydrogen, C_1 to C_6 alkyl, and aryl, R_5 and R_6 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl or R_5 and R_6 taken together to form a 4, 5, or 6 membered ring; R_7 and R_8 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_9 is selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_{10} is selected from $-(\text{C}=\text{O})\text{NR}_5\text{R}_6$ and $-\text{SO}_2\text{NR}_5\text{R}_6$, wherein R_5 and R_6 are defined as above, and $-\text{NR}_7(\text{C}=\text{O})\text{R}_8$, $-\text{NR}_7\text{SO}_2\text{R}_8$, $-\text{NR}_7(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-\text{S}(\text{O})_x\text{R}_8$ and $-\text{NR}_7(\text{C}=\text{O})\text{OR}_9$, wherein R_7 , R_8 , R_9 and x are defined as above; y is 0, 1, or 2; R_{11} is selected from C_1 to C_6 alkyl, benzyl and aryl; and the above aryl groups and the aryl moieties of the above

20

25

30


35

-68-

alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₄ alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C₁ to C₄ alkoxy.

10. The R enantiomer of a compound according to claim 9.

11. A compound according to claim 9, said compound being a compound of the formula




wherein n, R₁, R₂ and R₁₁ are as defined in claim 9.

12. The R enantiomer of a compound according to claim 11.

13. A compound according to claim 11 wherein R₁ is hydrogen; R₂ is -(CH₂)_m-SO₂NHR₃, -(CH₂)_m-NHSO₂R₃, -(CH₂)_m-SO₂R₃, -(CH₂)_m-(C=O)NHR₃ or -(CH₂)_m-NH(C=O)R₃; m is 0, 1, 2, or 3; R₃ is hydrogen, C₁ to C₆ alkyl, aryl, or C₁ to C₃ alkyl-aryl; R₁₁ is selected from C₁ to C₆ alkyl, benzyl and aryl; and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C₁ to C₄ alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C₁ to C₄ alkoxy.

14. A compound according to claim 9, said compound being a compound of the formula

-69-



III


5

wherein n , R_1 , R_3 and R_{10} are as defined in claim 9.

15. The R enantiomer of a compound according to claim 14.

16. A compound according to claim 14 wherein R_1 is hydrogen; R_3 is hydrogen or methyl; and R_{10} is $-\text{SO}_2\text{NHR}_5$, NHSO_2R_8 , $-\text{SO}_2\text{R}_8$, $-(\text{C}=\text{O})\text{NHR}_5$ or $-\text{NH}(\text{C}=\text{O})\text{R}_8$, wherein R_5 and R_8 are as defined in claim 9.

17. A process for preparing a compound of the formula



I

20


wherein n is 0, 1, or 2; R_1 is hydrogen; R_2 is selected from hydrogen, halogen, cyano, OR_4 , $-(\text{CH}_2)_m-(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{SO}_2\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{R}_8$, $-(\text{CH}_2)_m-\text{NR}_7\text{SO}_2\text{R}_8$, $-(\text{CH}_2)_m-\text{S}(\text{O})_x\text{R}_8$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{OR}_9$, and $-\text{CH}=\text{CH}(\text{CH}_2)_y\text{R}_{10}$; R_3 is selected from hydrogen and C_1 to C_6 linear or branched alkyl; R_4 is selected from hydrogen, C_1 to C_6 alkyl, and aryl; R_5 and R_6 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl or R_5 and R_6 taken together to form a 4, 5, or 6 membered ring; R_7 and R_8 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_9

30

-70-

is selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_{10} is selected from $-(C=O)NR_5R_6$ and $-SO_2NR_5R_6$, wherein R_5 and R_6 are defined as above, and $-NR_7(C=O)R_8$, $-NR_7SO_2R_8$, $-NR_7(C=O)NR_5R_6$, $-S(O)_xR_8$ and $-NR_7(C=O)OR_9$, wherein R_7 , R_8 , and R_9 are as defined above; y is 0, 1, or 2; x is 1 or 2; m is 0, 1, 2, or 3; and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy, comprising

(a) reducing a compound of the formula



where Q is CH_2 or $C=O$, W is $-CO_2R_{11}$ or R_3 , and R_{11} is C_1 to C_6 alkyl, benzyl, or aryl, and R_1 , R_2 , and R_{11} are as defined above;

(b) where R_2 is $-CH=CH(CH_2)_nR_{10}$ and R_{10} is as defined above by reacting a compound of formula I where R_3 is H or C_1 to C_6 linear or branched alkyl and R_2 is halogen and R_1 is defined as above with a compound of the formula $CH_2=CH(CH_2)_nR_{10}$ where R_{10} is as defined above using transition metal catalysis; or

(c) reacting the compound of formula I where R_3 is hydrogen and R_1 and R_2 are as defined above with a compound of the formula R_3-Z where R_3 is C_1 to C_6 linear or branched alkyl and Z is halogen and base; and,

if desired, converting a compound of formula I to a the pharmaceutically acceptable salts thereof.

-71-

18. The process according to claim 17 wherein the compound of formula I is an R enantiomer.

19. A process according to claim 17 wherein for the compound of formula I, R_1 is hydrogen; R_2 is $-(CH_2)_m-SO_2NHR_3$, $-(CH_2)_m-NHSO_2R_3$, $-(CH_2)_m-SO_2R_3$, $-(CH_2)_m-(C=O)NHR_3$, or $-(CH_2)_m-NH(C=O)R_3$; R_3 is hydrogen or methyl; and m , R_3 and R_3 are as defined in claim 17.

20. A process according to claim 17, said compound of formula I being selected from:

10 (R)-5-methoxy-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-bromo-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

15 (R)-5-(2-ethylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-methylaminosulfonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-methylaminosulfonyl-ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole;

20 (R)-5-(2-methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-carboxamido-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

25 (R)-5-(2-methylsulfonyl-ethyl)-3-(N-methylpyrrolidin-2-yl-methyl)-1H-indole;

(R)-5-(2-methylsulfonylamidoethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-aminosulphonyl-ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

30 (R)-5-(2-aminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-N,N-dimethylaminosulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

35 (R)-5-(2-phenylsulphonyl-ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;

-72-

(R)-5-(2-ethylsulphonyl ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole hemisuccinate;

(R)-5-(2-phenylsulphonyl ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

5 (R)-5-(3-benzenecarbonylamino prop-1-enyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-(4-methylphenylsulphonyl) ethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;

10 (R)-5-(3-methylsulphonylamino prop-1-enyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole;


(R)-5-(2-ethylsulphonyl ethyl)-3-(N-2-propylpyrrolidin-2-ylmethyl)-1H-indole;

(R)-5-(2-ethylsulphonyl ethyl)-3-(pyrrolidin-2-ylmethyl)-1H-indole;

15 (R)-5-(2-(4-methylphenylsulphonyl) ethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole; and

(R)-5-(2-methylsulfonyl methyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole.

20 21. A process for preparing a compound of the formula



25

wherein W is $-\text{CO}_2\text{R}_{11}$ or R_3 ; Q is CH_2 or $\text{C}=\text{O}$; n is 0, 1 or 2; R_1 is hydrogen; R_2 is selected from hydrogen, halogen, cyano, OR_4 , $-(\text{CH}_2)_m-(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{SO}_2\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{R}_8$, $-(\text{CH}_2)_m-\text{NR}_7\text{SO}_2\text{R}_8$, $-(\text{CH}_2)_m-\text{S}(\text{O})_x\text{R}_8$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{NR}_5\text{R}_6$, $-(\text{CH}_2)_m-\text{NR}_7(\text{C}=\text{O})\text{OR}_9$, and $-\text{CH}=\text{CH}(\text{CH}_2)_y\text{R}_{10}$; x is 1 or 2; m is 0, 1, 2, or 3; R_3 is selected from hydrogen and C_1 to C_6 linear or branched alkyl; R_4 is selected from hydrogen, C_1 to C_6 alkyl, and aryl, R_5 and R_6 are


30

35

-73-

independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl or R_5 and R_6 taken together to form a 4, 5, or 6 membered ring; R_7 and R_8 are independently selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_9 is selected from hydrogen, C_1 to C_6 alkyl, aryl, and C_1 to C_3 alkyl-aryl; R_{10} is selected from $-(C=O)NR_5R_6$ and $-SO_2NR_5R_6$, wherein R_5 and R_6 are defined as above, and $-NR_7(C=O)R_8$, $-NR_7SO_2R_8$, $-NR_7(C=O)NR_5R_6$, $-S(O)_2R_8$ and $-NR_7(C=O)OR_9$, wherein R_7 , R_8 , R_9 and x are defined as above; y is 0, 1 or 2; R_{11} is selected from C_1 to C_6 alkyl, benzyl and aryl; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy, comprising

(a) where W is $-CO_2R_{11}$ and R_1 , R_2 , R_{11} , and Q are as defined above, by reacting a compound of the formula



25 wherein R_1 and R_2 are as defined above with an acid chloride of the formula $N-CO_2R_{11}$ -proline with base; or


(b) where W is R_3 , Q is CH_2 , and R_2 is $-CH=CH(CH_2)_yR_{10}$ and R_1 , R_3 , and R_{10} are as defined above, by reacting the compound of formula V where R_2 is halogen, W is R_3 , Q is CH_2 and R_1 and R_3 are as defined above with a compound of the formula $CH_2=CH(CH_2)_yR_{10}$ where R_{10} is as defined above using transition metal catalysis.

30

22. The process according to claim 21 wherein the compound of formula V is an R enantiomer.

-74-

23. A process according to claim 21, wherein said compound of formula V is a compound of the formula



10 wherein n , R_1 , R_2 and R_{11} are as defined in claim 21.


24. The process according to claim 23 wherein the compound of formula II is an R enantiomer.

25. A process according to claim 23 wherein for the compound of formula II, R_1 is hydrogen; R_2 is $-(CH_2)_m-SO_2NHR_3$, $-(CH_2)_m-NHSO_2R_3$, $-(CH_2)_m-SO_2R_3$, $-(CH_2)_m-(C=O)NHR_3$, or $-(CH_2)_m-NH(C=O)R_3$; m is 0, 1, 2, or 3; R_3 is hydrogen, C_1 to C_6 alkyl, aryl, or C_1 to C_3 alkyl-aryl; R_{11} is selected from C_1 to C_6 alkyl, benzyl and aryl; and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy.

15

20

25 26. A process according to claim 21, wherein said compound of formula V is a compound of the formula



wherein n , R_1 , R_3 and R_{10} are as defined in claim 21.

-75-

27. The process according to claim 26 wherein the compound of formula III is an R enantiomer.

28. A process according to claim 26 wherein for the compound of formula III R_1 is hydrogen; R_2 is hydrogen or methyl; and R_{10} is $-SO_2NHR_5$, $NHSO_2R_8$, $-SO_2R_8$, $-(C=O)NHR_5$ or $-NH(C=O)R_8$, wherein R_5 and R_8 are as defined in claim 21.

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate "all")⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1.5

C 07 D 403/06

A 61 K 31/40

C 07 D 401/06

II. FIELDS SEARCHEDMinimum Documentation Searched⁷

Classification System

Classification Symbols

Int.C1.5

C 07 D 403/06

C 07 D 401/06

C 07 D 209/00

Documentation Searched other than Minimum Documentation
to the extent that such Documents are Included in the Fields Searched⁸**III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹**

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	NL,C, 74786 (N.V. AMSTERDAMSCH CHININEFABRIEK) 15 May 1954, see the whole document ---	1,5
X	NL,C, 74527 (N.V. AMSTERDAMSCH CHININEFABRIEK) 15 April 1954, see examples 1,7,8 ---	1,5
X	Journal of the American Chemical Society, vol. 79, 1957, Columbus, Ohio (US) H. Bader et al.: "Synthetic oxytocics. I. Synthesis and reactions of 3-indolyl-2'-pyridylcarbinols and of 2,3-(2',3'-indolo)-hexahydroquinolizines", pages 5686-5689, see compounds II and IV --- -/-	1

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

05-02-1992

Date of Mailing of this International Search Report

17. 03. 92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer


 Miss T. MORTENSEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	The Journal of Organic Chemistry, vol. 23, 1958, Columbus, Ohio (US), A.P. Gray: "Reductive alkylation of indole with pyridinecarboxaldehydes", pages 1453-1454, see compound III ---	1
X	The Journal of Organic Chemistry, vol. 29, 1964, Columbus, Ohio (US), J.A. Moore et al.: "The oxidative cyclization of 2,5-dihydroxyphenylalkylamines to 5-hydroxyindoles and 6-hydroxyquinolines", pages 2860-2864, see page 2863, compound 12 ---	1
X	Journal of the American Chemical Society, vol. 105, 1983, Columbus, Ohio (US) M. Cain et al.: "Selenium dioxide oxidations in the indole area. Synthesis of beta-carboline alkaloids", pages 907-913, see pages 908,911,912; compounds 15a,15b,16a,16b ---	1,9
X	GB,A, 851780 (SOC. DES USINES CHIMIQUES RHONE-POULENC) 19 October 1960, see page 2, right-hand column, lines 53,54; page 3, left-hand column, lines 1,2 ---	1
X	US,A,2773875 (HOFFMANN-LA ROCHE) 11 December 1956, see the whole document ---	1
X	Tetrahedron, vol. 38, no. 1, 1982, Pergamon Press Ltd (GB) N. Mohr et al.: "Tilivalline, a new pyrrolo[2,1-c][1,4] benzodiazepine metabolite from Klebsiella", pages 147-152, see page 151, compounds 11,12 ---	1,9,11
X	Chemical Abstracts, vol. 83, 1975, Columbus, Ohio (US) E. Friderichs et al.: "Serotonin derivatives with cyclic side chains. 1. Isomeric 3-(pyridylmethyl)- and 3-(piperidylmethyl)-5-hydroxyindoles", see page 492, abstract 28056k, & Arch. Pharm. (Weinheim, Ger), 1975, 308(3), 209-17 (RN 55818-09-2; RN 55817-97-5) ---	1
A	GB,A, 893707 (ROCHE PRODUCTS LTD) 11 April 1962, see the whole document ---	1,5
A	GB,A, 886684 (THE UPJOHN CO.) 10 January 1962, see the whole document --- -/-	1,5

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	GB,A, 966562 (PARKE, DAVIS & CO.) 12 August 1964, see the whole document ---	1,5
A	GB,A,2081717 (GLAXO GROUP LTD) 24 February 1982, see the whole document ---	1,5
A	US,A,3037031 (WARNER-LAMBERT PHARM. CO.) 29 May 1962, see page 1 ---	1,5
A	US,A,4803218 (MCNEILAB, INC.) 7 February 1989, see columns 1,2 -----	1,5

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9107194
SA 53524

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 11/03/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
NL-C- 74786		None	
NL-C- 74527		None	
GB-A- 851780		None	
US-A- 2773875		None	
GB-A- 893707		None	
GB-A- 886684		None	
GB-A- 966562		None	
GB-A- 2081717	24-02-82	AU-B- 550010	27-02-86
		AU-A- 7399581	18-02-82
		AU-B- 548270	05-12-85
		AU-A- 7399681	18-02-82
		BE-A- 889930	11-02-82
		CA-A- 1169077	12-06-84
		CA-A- 1169429	19-06-84
		CH-A- 651550	30-09-85
		CH-A- 652394	15-11-85
		DE-A- 3131748	01-04-82
		DE-A- 3131752	16-06-82
		FR-A, B 2488605	19-02-82
		FR-A, B 2488606	19-02-82
		GB-A, B 2083463	24-03-82
		JP-B- 1048895	20-10-89
		JP-C- 1565595	25-06-90
		JP-A- 57059864	10-04-82
		LU-A- 83546	08-06-83
		NL-A- 8103764	01-03-82
		NL-A- 8103768	01-03-82
		SE-B- 454881	06-06-88
		SE-A- 8104782	13-02-82
		SE-B- 454777	30-05-88
		SE-A- 8104783	13-02-82
		US-A- 4672067	09-06-87

EPO FORM P047

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

Page 2

US 9107194
SA 53524

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on 11/03/92
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 2081717		US-A- 4636521	13-01-87
US-A- 3037031		None	
US-A- 4803218	07-02-89	None	

EPD FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82